EP3143143A1 - Antagonisten von slc38a9 und deren verwendung in der therapie - Google Patents

Antagonisten von slc38a9 und deren verwendung in der therapie

Info

Publication number
EP3143143A1
EP3143143A1 EP15727569.4A EP15727569A EP3143143A1 EP 3143143 A1 EP3143143 A1 EP 3143143A1 EP 15727569 A EP15727569 A EP 15727569A EP 3143143 A1 EP3143143 A1 EP 3143143A1
Authority
EP
European Patent Office
Prior art keywords
slc38a9
nucleic acid
seq
antagonist
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP15727569.4A
Other languages
English (en)
French (fr)
Inventor
Manuele REBSAMEN
Giulio Superti-Furga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CEMM Forschungszentrum fuer Molekulare Medizin GmbH
Original Assignee
CEMM Forschungszentrum fuer Molekulare Medizin GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CEMM Forschungszentrum fuer Molekulare Medizin GmbH filed Critical CEMM Forschungszentrum fuer Molekulare Medizin GmbH
Publication of EP3143143A1 publication Critical patent/EP3143143A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Definitions

  • the present invention relates to an antagonist or modulator of SLC38A9 for use in treating a disease associated with mTORCl activation, like a proliferative disease (e.g. a cancerous disease or benign proliferative disease), a metabolic disorder, a disorder of the immune system, a disorder causing premature aging, an ophthalmic disorder or a neurological disorder.
  • a proliferative disease e.g. a cancerous disease or benign proliferative disease
  • a metabolic disorder e.g. a cancerous disease or benign proliferative disease
  • a disorder of the immune system e.g. a cancerous disease or benign proliferative disease
  • a disorder of the immune system e.g. a disorder of the immune system
  • a disorder causing premature aging e.g. a ophthalmic disorder or a neurological disorder.
  • exemplary diseases to be treated are cancerous diseases like lung cancer, breast cancer, bladder cancer, pancreatic cancer, ovarian cancer, colon carcinoma, le
  • Also provided herein are methods for treating, preventing or ameliorating such diseases comprising the administration of an antagonist of SLC38A9 to a subject in need of such a treatment, prevention or amelioration. Furthermore, the present invention provides methods for assessing the activity of a candidate molecule suspected of being an antagonist of SLC38A9 and identification of such antagonists.
  • rapamycin complex 1 integrates the presence of growth factors, energy levels, glucose and amino acid availability to modulate metabolic status and cellular responses 1 ' 2 .
  • mTORCl is recruited to the surface of lysosomes by RAG GTPases and the Ragulator in dependence of amino acid availability 3"5 .
  • Aberrant activation of mTORCl in known in the art to be implicated in several disease, and in particular metabolic disorders like type 2 diabetes as well as in proliferative malignancies like cancer.
  • Compounds targeting mTORCl (such as rapamycin and rapamycin analogs) are tested in clinical trials and some compounds have already been approved by the FDA.
  • the Ragulator complex tethers the RAG GTPases to the lysosome and, in presence of amino acids, acts as a guanine nucleotide exchange factor (GEF) for RAGA/B 14 .
  • RAG GTPases function as heterodimers of RAGA/B with RAGC/D and in their active nucleotide loaded state, RAGA/B GTP -RAGC/D GDP , bind RAPTOR and recruit mTORCl to the lysosomal surface where it is activated by RHEB.
  • the nature of the amino acid sensor has remained mysterious 1 ' 6 ' 8 .
  • the technical problem underlying the present invention is the provision of means and methods for the medical intervention in diseases associated with aberrant mTORCl activation.
  • the present invention relates to an antagonist of SLC38A9 for use in treating a disease associated with mTORCl activation, in particular aberrant mTORCl activation.
  • the present invention relates to a method for treating, preventing or ameliorating a disease associated with mTORCl activation (in particular aberrant mTORCl activation) comprising the administration of an antagonist of SLC38A9 to a subject in need of such a treatment, prevention or amelioration.
  • a disease associated with mTORCl activation in particular aberrant mTORCl activation
  • the subject or patient to be treated in accordance with the present invention is a human.
  • the present invention solves the above identified technical problem since, as documented herein below and in the appended examples, it was surprisingly found that the so far uncharacterized human member 9 of the solute carrier family 38 (SLC38A9, Senior) is a lysosomal membrane resident protein competent in amino acid transport that control mTORCl activation. Extensive functional proteomic analysis established Senior as an integral part of the Ragulator/RAG GTPases machinery. 'Antagonists of SLC38A9" to be used in accordance with the present invention and assays for identifying or validating these antagonists are described further below.
  • the mTOR complex 1 (mTORCl) is composed of mTOR, a serine/threonine kinase (Uniprot: P42345), Raptor (Uniprot: Q8N122); mLST8 (Uniprot: Q9BVC4), Deptor (Uniprot : Q8TB45) and PRAS40 (Uniprot : Q96B36).
  • mTOR complex 1 a serine/threonine kinase
  • Raptor Uniprot: Q8N122
  • mLST8 Uniprot: Q9BVC4
  • Deptor Uniprot : Q8TB45
  • PRAS40 Uniprot : Q96B36
  • Exemplary nucleotide sequences and amino acid sequences of the mTOR complex 1 are shown in SEQ ID NO: 23-52.
  • the terms "mTOR complex 1" and "mTORCl” are used interchangeably herein. Aberrant activation of mTORC
  • siRNA small interfering RNA
  • mTORCl is involved in cell growth 21 and is hence a driving factor in the development and progress of diseases associated with mTORCl activation (in particular aberrant mTORCl activation), like proliferative diseases or metabolic disorders, the use of antagonists of SLC38A9 as shown and described herein, provides for a clear rationale for the use of such antagonists in the therapy of diseases associated with (aberrant) mTORCl activation.
  • mTORCl Aberrant activation of mTORCl in known in the art to be implicated in several disease, and in particular metabolic disorders like type 2 diabetes as well as in proliferative malignancies like cancer as described, inter alai, in Cornu (Current opinion in genetics & development 23, 53- 62, doi: 10.1016/j.gde.2012.12.005 (2013)), Laplante (Cell 149, 274-293, doi: 10.1016/j.cell.2012.03.017 (2012)), Shaw (Nature 441, 424-430, doi: 10.1038/nature04869 (2006)) and Efeyan (Trends Mol Med, 2012. 18(9): p. 524-33.)).
  • Senior is a physical and functional component of the amino acid-sensing complex that controls the activation of mTOR.
  • amino acids are essential for mTORCl activity, as growth factors cannot efficiently activate mTOR in their absence 4 ' 9 , targeting Senior affects a crucial mechanism required for mTORCl activation. Therefore, antagonists of Senior can credibly be used in the treatment of diseases associated with (aberrant) mTORCl activation.
  • SLC38A9 displays the characteristics expected for the lysosomal amino acid sensor required for activation of mTOR. Therefore, SLC38A9 is termed herein “Senior” ("sensor of mTOR”).
  • Sensor of mTOR The terms “SLC38A9” and “Senior” are used interchangeably herein.
  • SLC38A9 refers to member 9 of the SLC38 family.
  • SLC38 also known as sodium-coupled neutral amino acid transporter, SNAT
  • SNAT sodium-coupled neutral amino acid transporter
  • nucleic acid sequences can be retrieved in public databases like NCBI using the following accession numbers:
  • Isoform4 NP 001269358.1
  • isoform 1 of SLC38A9 An exemplary amino acid sequence of said isoform 1 is shown in SEQ ID NO. 3.
  • Corresponding exemplary nucleic acid sequences are shown in SEQ ID NO: 1, 2 or 4.
  • SEQ ID 1 or 2 show DNA sequences; whereas SEQ ID NO. 4 shows an mRNA sequence.
  • SLC38A9 being encoded by these nucleic acid sequences (or having this amino acid sequence) and being encoded by or having related sequences is, accordingly, preferred herein.
  • SLC38A9 refers primarily to a protein. It is believed that “SLC38A9” can act as monomer or dimer. Thus, the term “SLC38A9” can refer to a monomer or dimer of a SLC38A9 protein as defined herein, in particular a monomer or dimer of isoform 1 of SLC38A9.
  • SLC38A9 to be used herein can be selected from the group consisting of
  • the SLC38A9 to be used herein is selected from the group consisting of
  • a polypeptide comprising an amino acid encoded by a nucleic acid molecule hybridizing under stringent conditions to the complementary strand of nucleic acid molecules as defined in (a) or (c); (e) a polypeptide having at least 70 % identity, preferably at least 90 % identity, particularly preferably at least 99 % identity, to the polypeptide of any one of (a) to (d); and
  • the SLC38A9 to be used herein is selected from the group consisting of
  • SLC38A9 to be used herein in particular isoform 1 of SLC38A9 as defined herein, has the capacity/activity to transport amino acids and/or to bind to amino acids, particularly glutamine and cysteine; see Fig. 3c-d and 10c. Also related amino acids can be transported and/or bound, like selenocysteine. The other amino acids shown in Fig. 3d can be bound and/or transported.
  • Fig. 3d exemplifies the binding preference of SLC38A9 for amino acids (so that SLC38A9 has the highest binding capacity for glutamine and cysteine and the lowest binding capacity for alanine).
  • the binding preference reflects the transport preference (so that SLC38A9 has the highest transport capacity for glutamine and cysteine and lowest transport capacity for alanine).
  • SLC38A9 to be used herein has primarily the capacity/activity to transport amino acids, particularly glutamine, cysteine (or selenocysteine), or other amino acids. By transporting and/or binding to amino acids, particularly glutamine and cysteine (or selenocysteine), or other amino acids, SLC38A9 acts as sensor of the amino acid status and hence as activator of mTORC 1.
  • transmembrane region of the SLC38A9 protein is primarily important for the activity of SLC38A9 to transport and/or bind to amino acids, in particular glutamine and cysteine.
  • the capacity/activity to transport amino acids and/or to bind to amino acids, particularly glutamine, resides in the eleven transmembrane-containing regions (113-561) of isoform 1 of SLC38A9. Accordingly, antagonists of SLC38A9 to be used herein interfere, in particular, inhibit/antagonize in particular this transport and/or binding activity/capacity. Therefore, the transmembrane region is the primary target of antagonists of SLC38A9 to be used and/or identified in accordance with the present invention.
  • Isoform 1 amino acid sequence:
  • transmembrane (-containing) regions of SLC38A9 can be selected from the group consisting of
  • polypeptide having at least 70 % identity, preferably at least 90 %, particularly preferably at least 99 %, to the polypeptide of any one of (a) to (d);
  • the "transmembrane (-containing) region of SLC38A9" to be used herein is selected from the group consisting of
  • polypeptide having at least 70 % identity, preferably at least 90 %, particularly preferably at least 99 %, to the polypeptide of any one of (a) to (d);
  • SLC38A9 is important for interaction with the Ragulator/RAG GTPases complex, for example for interaction with LAMTOR1, LAMTOR3, RAGA and RAGC proteins.
  • SLC38A9 (isoform 1) deletion constructs encoding the N-terminal cytoplasmic tail (amino acids 1-112) of isoform 1 of SLC38A9 were generated. It was demonstrated that the cytoplasmic region of SLC38A9 (isoform 1) retained the ability to interact with endogenous LAMTOR1, LAMTOR3, RAGA and RAGC proteins similar to the full-length protein, whereas binding was completely lost when the region was deleted (FIG 2D). This indicated that the cytoplasmic tail, devoid of any transmembrane region, is required and sufficient to bind the Ragulator/RAG GTPases complex.
  • SLC38A9 to be used herein in particular isoform 1 of SLC38A9 as defined herein, has, accordingly, the capacity/activity to interact with the Ragulator/RAG GTPases complex, for example the capacity/activity to interact with LAMTOR1, LAMTOR3, RAGA and/or RAGC protein(s).
  • Transport of amino acids by SLC38A9 can influence the interaction with/binding to the Ragulator/ RAG GTPases complex and/or modify the activity of RAG GTPases.
  • the cytoplasmic region of SLC38A9 is a target region for the antagonists of SLC38A9 to be used herein.
  • antagonists of SLC38A9 may interfere with or inhibit interaction of SLC38A9 with binding partners, in particular with the Ragulator/RAG GTPases complex as defined herein, and thereby antagonize SLC38A9 (activity).
  • small molecule drugs or binding molecules to be used as antagonists of SLC38A9 herein can antagonize SLC38A9 by specifically binding to the cytoplasmic region of the SLC38A9 protein (or parts thereof and/or conserved motifs thereof as defined further below).
  • Aptamers, intramers (in particular oligonucleic acid aptamers/intramers), siRNA, shRNA, miRNA, dsRNA, stRNA, antisense molecules and the like to be used as antagonists of SLC38A9 herein can antagonize SLC38A9 by specifically binding to a nucleic acid molecule having a sequence encoding the cytoplasmic region of the SLC38A9 protein (or parts thereof and/or conserved motifs thereof as defined further below).
  • cytoplasmic region of SLC38A9 refers primarily to the N-terminal amino acid sequence of SLC38A9, i.e. the amino acid sequence of the full-length SLC38A9 protein excluding the eleven transmembrane-containing regions.
  • a preferred "cytoplasmic region of SLC38A9" to be used herein is the "cytoplasmic region of isoform 1 of SLC38A9".
  • the N-terminal cytoplasmic region of SLC38A9 ranges from amino acid positions 1 to 120 of the full length protein (e.g. as shown in SEQ ID NO. 3).
  • the N-terminal cytoplasmic region of SLC38A9 (isoform 1) of from amino acid positions 1 to 111, or of from amino acid positions 1 to 112, of the full length protein (e.g. as shown in SEQ ID NO. 3) is the part that is shown herein to be required for the binding to the RAG/Ragulator complex.
  • cytoplasmic parts of the SLC38A9 protein are not sufficient to bind RAG/ragulator as deletion of amino acids 1-112 abrogates binding. Yet, these cytoplasmic parts may also be a valuable target for antagonists to be used herein, e.g. in addition to the N-terminal cytoplasmic region of SLC38A9 as defined herein.
  • the N-terminal cytoplasmic region corresponds to (i.e. consists of) amino acids 1 to 11 1, more preferably to amino acids 1 to 112, of the full length SLC38A9 protein.
  • An exemplary sequence of a full length SLC38A9 protein of the herein preferred isoform 1 is shown in SEQ ID NO. 3.
  • An accordingly preferred N-terminal cytoplasmic region of SLC38A9 protein is as follows:
  • a corresponding nucleic acid sequence is as follows:
  • a herein preferred N-terminal cytoplasmic region of SLC38A9 protein corresponding to (i.e. consisting of) amino acids 1 to 112 of the full length SLC38A9 protein is as follows:
  • a corresponding nucleic acid sequence is as follows:
  • Isoforms 2, 3 and 4 of SLC38A9 may, like isoform 1, have the capacity to interact with the RAG/Ragulator complex.
  • isoforms 2 and 3 of SLC38A9 may have the capacity to bind to the RAG/Ragulator complex.
  • isoforms 2, 3 and 4 of SLC38A9 may, like isoform 1, have the capacity to bind to/transport amino acids. It may also be that isoforms 2, 3 and 4 of SLC38A9 interact with isoform 1, potentially supporting its activity.
  • antagonizing/antagonists of isoforms 2, 3 and 4 of SLC38A9 (as defined herein further below) in accordance with the present invention is envisaged herein, too.
  • isoform2 lack amino acids 1 to 63
  • isoform 3 lacks amino acids 1 to 37 that are substituted with: MAICILTWRI
  • Isoform 4 lacks amino acids 1 to 124.
  • N-terminal cytoplasmic regions of isoforms 2 and 3 of the SLC38A9 protein that correspond to the N-terminal cytoplasmic region of isoform 1 , in particular amino acids 1 to 111 , and that may serve as targets for antagonists provided herein are as follows: Isoform 2 (aa 1-48 corresponding to the 1- 111 region of iso form 1):
  • Isoform 3 (aa 1-84 corresponding to the 1-111 region of isoform 1):
  • N-terminal cytoplasmic regions of iso forms 2 and 3 of the SLC38A9 protein that correspond to the N-terminal cytoplasmic region of isoform 1, in particular amino acids 1 to 112, and that may serve as targets for antagonists provided herein are as follows:
  • Isoform 2 (aa 1-49 corresponding to the 1-112 region of isoform 1):
  • cytoplasmic region of SLC38A9 can be selected from the group consisting of
  • polypeptide having at least 70 % identity, preferably at least 90 %, particularly preferably at least 99 %, to the polypeptide of any one of (a) to (d);
  • cytoplasmic region of SLC38A9 is selected from the group consisting of
  • polypeptide having at least 70 % identity, preferably at least 90 %, particularly preferably at least 99 %, to the polypeptide of any one of (a) to (d);
  • antagonists of SLC38A9 that specifically target the amino acid sequence corresponding to positions 31-111 of isoform 1 of SLC38A9 (protein), particularly antagonists of SLC38A9 that specifically target the amino acid sequence corresponding to positions 31-112 of isoform 1 of SLC38A9.
  • Amino acid sequence of amino acids 31-111 of isoform 1 isoform 1 :
  • PSDLRSKRPFCIEPTNIVNVNHVIQRVSDHASAMNKRIHYYSRLTTPADKALIAPDHV VPAPEECYVYSPLGSAYKLQSYT (SEQ ID NO: 58)
  • Nucleotide sequence encoding amino acids 1 to 48 of isoform 2 (corresponding to amino acids 64-111 of isoform 1): ATGAACAAGAGAATTCATTACTACAGCCGGCTCACCACTCCTGCAGACAAGGCAC TGATTGCCCCAGACCATGTAGTTCCAGCTCCAGAAGAGTGCTATGTGTATAGTCC ATTGGGCTCTGCTTATAAACTTCAAAGTTACACT (SEQ ID NO: 59)
  • Amino acid sequence of amino acids 1 to 48 of isoform 2 (corresponding to the 64-111 region of isoform 1):
  • Nucleotide sequence encoding amino acids 11 to 84 of isoform 3 (corresponding to amino acids 31-111 of isoform 1):
  • Amino acid sequence of amino acids 11 to 84 of isoform 3 (corresponding to amino acids S il l 1 of isoform 1):
  • Amino acid sequence of amino acids 31-112 of isoform 1 isoform 1 :
  • PSDLRSKRPFCIEPTNIVNVNHVIQRVSDHASAMNKRIHYYSRLTTPADKALIAPDHV VPAPEECYVYSPLGSAYKLQSYTE (SEQ ID NO: 103) Nucleotide sequence encoding amino acids 1 to 49 of isoform 2 (corresponding to amino acids 64-112 of isoform 1):
  • Amino acid sequence of amino acids 1 to 49 of isoform 2 (corresponding to the 64-112 region of isoform 1):
  • Amino acid sequence of amino acids 11 to 85 of isoform 3 (corresponding to amino acids 31- 112 of isoform 1):
  • cytoplasmic region of SLC38A9 can be selected from the group consisting of
  • polypeptide having at least 70 % identity, preferably at least 90 %, particularly preferably at least 99 %, to the polypeptide of any one of (a) to (d);
  • the "cytoplasmic region of SLC38A9" to be used herein is selected from the group consisting of
  • polypeptide having at least 70 % identity, preferably at least 90 %, particularly preferably at least 99 %, to the polypeptide of any one of (a) to (d);
  • antagonists of SLC38A9 that specifically target the amino acid sequences corresponding to amino acid positions 38-40 of isoform 1 of the SLC38A9 protein, 70 to 73 of isoform 1 of the SLC38A9 protein and/or 85 to 87 of isoform 1 of the SLC38A9 protein.
  • the following relates to diseases associated with mTORCl activation, in particular aberrant mTORCl activation.
  • siRNA small interfering RNA
  • silencing of SLC38A9 suppressed amino acid- induced mTORCl activation with similar efficiency as silencing of the positive control Lamtorl (FIG 4C).
  • the shRNA to be used herein can target the 5' UTR.
  • the siRNA to be used herein can target regions that are encoding for the cytoplasmic region.
  • mTORCl is involved in cell growth 21 and is hence, a driving factor in the development and progress of diseases associated with mTORCl activation, like proliferative diseases or metabolic disorders, the use of antagonists of SLC38A9 as shown herein, provides for a scientific rationale in the therapy of such diseases.
  • the mTOR complex 1 is composed of Raptor (Uniprot: Q8N122); mTOR (Uniprot: P42345), mLST8 (Uniprot: Q9BVC4), Deptor (Uniprot : Q8TB45) and PRAS40 (Uniprot : Q96B36).
  • Raptor Uniprot: Q8N122
  • mTOR Uniprot: P42345
  • mLST8 Uniprot: Q9BVC4
  • Deptor Uniprot : Q8TB45
  • PRAS40 Uniprot : Q96B36
  • Exemplary nucleotide sequences and amino acid sequences of the mTOR complex 1 are shown in SEQ ID NO: 23-52.
  • the terms "mTOR complex 1" and "mTORCl” are used interchangeably herein.
  • mTOR is a serine/threonine kinase that associate in a large protein complex with RAPTOR, mLST
  • mTORCl integrate signals from growth factors, energy levels and nutrient availability to control critical cellular process, such as protein translation, ribosome biogenesis, lipid synthesis, energy metabolism, lysosome biogenesis and autophagy. Therefore, mTORCl is at the center of the cell decision of engaging anabolic or catabolic programs.
  • mTORC 1 activity can be measured by monitoring the phosphorylation of its target substrates, such as S6 kinase and/or 4E-BP1 to control protein synthesis or ULK1 for autophagy regulation (as shown in Figure 4 as well as in references 4, 5, 13 and 14).
  • Aberrant mTORCl activation can be measured by an increase in phosphorylation of its target substrates, for example S6 kinase and/or 4E-BP1, in disease patient samples when compared the corresponding healthy tissue using for example immunohistochemistry or immunoblot.
  • target substrates for example S6 kinase and/or 4E-BP1
  • mTORCl Aberrant activation of mTORCl is known in the art to be implicated in several disease, and in particular metabolic disorders like type 2 diabetes as well as in proliferative malignancies like cancer as described in ref 7, 8, 21 and (Efeyan, A., R. Zoncu, and D.M. Sabatini, Amino acids and mTORCl : from lysosomes to disease. Trends Mol Med, 2012. 18(9): p. 524-33.).
  • Germline or somatic mutations in genes, oncogenes as well as tumor suppressor genes, resulting in increase mTORC 1 activity and thereby promoting tumor formation are known in the art (Efeyan, A., R. Zoncu, and D.M.
  • exemplary disease(s) associated with mTORCl activation to be treated in accordance with the present invention is/are (a) proliferative disease(s), (a) metabolic disorder(s), (a) disorder(s) of the immune system, (a) disorder(s) causing premature aging, (an) ophthalmic disorder(s) or (a) neurological disorder(s).
  • An exemplary disorder of the immune system to be treated in accordance with the present invention is/are autoimmune diseases such as systemic lupus erythematosus (Fernandez, D. and A. Perl, mTOR signaling: a central pathway to pathogenesis in systemic lupus erythematosus? Discov Med, 2010. 9(46): p. 173-8 and Yang, H., et al, Modulation of TSC- mTOR signaling on immune cells in immunity and autoimmunity. J Cell Physiol, 2014. 229(1): p. 17-26.)
  • An exemplary disorder causing premature aging to be treated in accordance with the present invention is Hutchinson-Gilford progeria syndrome (Graziotto, J.J., et al., Rapamycin activates autophagy in Hutchinson-Gilford progeria syndrome: implications for normal aging and age-dependent neurodegenerative disorders. Autophagy, 2012. 8(1): p. 147-51.)
  • An exemplary disorder of an ophthalmic disorder to be treated in accordance with the present invention is age-related macular degeneration (Zhao, C. and D. Vollrath, mTOR pathway activation in age-related retinal disease. Aging (Albany NY), 2011. 3(4): p. 346-7).
  • An exemplary disorder of a neurological disorder to be treated in accordance with the present invention is Huntington's, Parkinson's, Alzheimer's disease (mentioned for example in ref 8).
  • Proliferative disease(s) to be treated herein is/are (a) cancerous disease(s) or (a) benign proliferative disease(s).
  • An exemplary benign proliferative disease(s) to be treated in accordance with the present invention is tuberous sclerosis.
  • cancerous disease(s) is/are lung cancer, breast cancer, bladder cancer, pancreatic cancer, ovarian cancer, colon carcinoma, leukemia, lymphoma, melanoma, esophageal cancer or stomach cancer.
  • the following references disclose that metabolic disorders and cancerous diseases are causally linked to aberrant mTORC 1 activation.
  • the references also disclose (animal) models of these diseases.
  • These and other suitable (animal) models are known in the art and can be used to validate that the herein provided antagonists of SLC38A9 can be used in the therapy of these diseases/disorders.
  • Colon carcinoma APC(Min/+) mice.
  • Pancreatic cancer Morran, D.C., et al., Targeting mTOR dependency in pancreatic cancer. Gut, 2014.
  • Ovarian cancer Wu, R., et al., Preclinical testing of PI3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma. Clin Cancer Res, 2011. 17(23): p. 7359-72.
  • metabolic disorder(s) to be treated herein can be characterized by 20% or more body fat in the subject to be treated.
  • exemplary metabolic disorder(s) to be treated in accordance with the present invention is/are overweight (pre-obesity), obesity or diabetes.
  • the diabetes is type 2 diabetes.
  • a suitable (animal) model of diabetes type 2 are db/db mice which are known in the art. This and other suitable models can be used to validate that the herein provided antagonists of SLC38A9 can be used in the therapy of metabolic disorders, such as diabetes type 2.
  • Obesity is a condition where excess body fat accumulates to such an extent that one's health may be affected; see Arner (2010) Biochem and Biophys Res Comm 396, 101 - 104.
  • obesity is increasing and constitutes a major health problem, as obesity also enhances the risk for cardiovascular disease and metabolic disorders such as type 2 diabetes; see Spalding (2008) Nature 453, 783-787.
  • Body mass index is a simple index of weight-for-height that is commonly used to classify overweight and obesity in adults. It is defined as a person's weight in kilograms divided by the square of his height in meters (kg/m 2 ).
  • an “overweight” patient is often defined as having a body mass index (BMI) above 25 kg/m 2 .
  • "overweight” is preferably defined as a body mass index (BMI) between 25 to 30 kg/m 2 and "obesity” is preferably defined as a body mass index (BMI) of higher than 30 kg/m 2 .
  • "Severe obesity” is usually defined as a body mass index (BMI) of 40 kg//m 2 and higher than 40 kg/m 2 .
  • raised BMI is a major risk factor for noncommunicable diseases such as cardiovascular diseases (mainly heart disease and stroke), diabetes, musculoskeletal disorders (especially osteoarthritis - a highly disabling degenerative disease of the joints) and some cancers (like endometrial cancer, breast cancer, and colon cancer).
  • cardiovascular diseases mainly heart disease and stroke
  • musculoskeletal disorders especially osteoarthritis - a highly disabling degenerative disease of the joints
  • some cancers like endometrial cancer, breast cancer, and colon cancer.
  • cancers like endometrial cancer, breast cancer, and colon cancer.
  • patients to be treated herein are overweight or obese children. It is known in the art that childhood obesity is associated with a higher chance of obesity, premature death and disability in adulthood. In addition to increased future risks, obese children experience breathing difficulties, increased risk of fractures, hypertension, early markers of cardiovascular disease, insulin resistance and psychological effects. Accordingly, the therapy of these patients (having, for example, childhood obesity) is envisaged in the present invention.
  • BMI provides the most useful population-level measure of overweight and obesity as it is the same for both sexes and for all ages of adults. However, it should be considered a rough guide because it may not correspond to the same degree of fatness in different individuals. In certain medically indicated cases, it is therefore envisaged that also patients with a BMI below 25 kg/m 2 can be assessed in accordance with the present invention. In the same vein, not every subject/patient with a high BMI (e.g. between 25 to 30 kg/m 2 or higher than 30 kg/m 2 ) is an "obese" or "overweight" patient - it is well known that individuals with greater than average muscle mass (e.g. certain athletes (like bodybuilders)) will have a higher BMI without having abnormal or excessive fat accumulation.
  • the patient that is to be treated in accordance with the present invention may be characterized by the presence of 20 % or more body fat in the subject/patient.
  • a body fat percentage of 25 % or more may be characteristic for an overweight/obese man
  • a body fat percentage of 32 % or more may be characteristic for an overweight/obese woman. It is known in the art that a person's body fat percentage is the total weight of the person's fat divided by the person's weight.
  • the body's fat consists of essential body fat and storage body fat.
  • Essential body fat is necessary to maintain life and reproductive functions.
  • Essential fat is usually 3%-5% in men, and 8-12% in women.
  • Storage body fat consists of fat accumulation in adipose tissue, part of which protects internal organs in the chest and abdomen.
  • the percentage of storage fat or extra fat as denoted herein may be calculated from the above given exemplary values. Yet, it is often difficult to exactly determine the percentage of essential fat and of storage fat. Therefore, the total fat percentage is routinely determined/estimated and used in the art in order to classify a subject/patient as overweight/obese.
  • Appropriate measurement techniques are known in the art and include Near-infrared interactance or Dual energy X-ray absorptiometry (DXA). Also multicompartment models can be used; these models can include DXA measurement of bone, plus independent measures of body water and body volume. Various other components may be independently measured, such as total body potassium.
  • in-vivo neutron activation can quantify all the elements of the body and use mathematical relations among the measured elements in the different components of the body (fat, water, protein, etc.) to develop simultaneous equations to estimate total body composition, including body fat.
  • body average density measurement can be used to determine a subject/patients body fat percentage: this technique involves the measurement of a person's average density (total mass divided by total volume) and the application of a formula to convert that to body fat percentage.
  • Bioelectrical impedance analysis is also a well known technique to estimate body fat percentage.
  • anthropometric methods (measurements made of various parameters of the human body, such as circumferences of various body parts or thicknesses of skinfolds) may be used.
  • the body fat percentage is obtained by applying a second formula, such as the Siri or Brozek formula. Further, Skinfold methods may applied and the body fat percentage may even be calculated from the BMI.
  • the body fat percentage of a male patient/subject to be treated herein is at least 18 %, 19 %, 20 %, 21 %, 22 %, 23 %, 24 % and more preferably, at least 25 %.
  • the body fat percentage of a female patient/subject to be treated herein is at least at least 25 %, 26 %, 27 %, 28 %, 29 %, more preferably 30 %, 31 % and even more preferably at least 32 %.
  • the identification of obese patients according to the body fat percentage may be especially advantageous in individuals having a BMI of below 30 kg/m 2 ; according to the bioelectrical impedance criterion a man may be considered obese in case of a body fat percentage of at least 25 % and a woman may be considered obese in case of a body fat percentage of at least 30 %; see Frankenfield (2001) Nutrition 17:26-30 which is incorporated in its entirety herein. Upper limits of body fat percentage will have to be calculated on an individual basis; yet, typically body fat percentage does not exceed about 60 % even in severely obese subjects/patients.
  • an obese/overweight patient to be treated herein may have higher levels of triglycerides in the blood of the patient.
  • the recommended level of triglycerides (in a normal range) is in males 40-160 mg/dL and in females 35 to 135 mg/dL. However, in Germany also "higher levels" are tolerated on being normal; e.g. 250 mg/dL. Accordingly, higher levels of triglycerides are preferably above 150 mg/dL, more preferably above 200 mg/dL and most preferably above 250 mg/dL. Accordingly, the patients to be treated in accordance with the present invention can have overweight, obesity, and/or eating disorders leading to increased BMI/body fat percentage/body weight/body mass as defined herein above.
  • drugs like corticosteroids, antipsychotic drugs, antidepressants, particularly tricyclic antidepressants, oral contraceptives, etc.
  • patients to be treated herein can suffer from secondary disorders related to a (pathological) increase of body weight/BMI/body fat percentage (e.g. overweight/obesity).
  • secondary disorders may comprise, but are not limited to diabetes type 2, high blood pressure (hypertension), cardio-vascular diseases, problems with sexual function and disorder of the muscular or bone system, and lipid disorders (such as hypertriglyceridemia and hypercholesterolemia), growth hormone deficiency, partial growth hormone deficiency or neuro-secretory dysfunction of growth hormone secretion.
  • Problems with sexual function may comprise libido problems, penile dysfunction as well as FSAD (Female Sexual Arousal Disorder).
  • dyslipidaemia may be a "secondary disorder”.
  • Secondary disorders of the metabolism linked to higher body weight/body mass/BMI/body fat percentage may also comprise, but are not limited to, glycogen storage diseases, lipid storage diseases (like Gaucher or Niemann Pick), endocrine disorders (like Cushings, hypothyroidism, insulinomas, lack of growth hormone, diabetes, adrenogenital syndrome, diseases of the adrenal cortex), tumors and metastases (such as craniopharyngeomas), Prader- Willi syndrome, Down syndrome and genetic diseases and syndromes (like, e.g., hyperlipoproteinemias, hypothalamic disorders, Frohlich syndrome or empty sella syndrome).
  • glycogen storage diseases like Gaucher or Niemann Pick
  • endocrine disorders like Cushings, hypothyroidism, insulinomas, lack of growth hormone, diabetes, adrenogenital syndrome, diseases of the adrenal cortex
  • tumors and metastases such as craniopharyngeomas
  • Prader- Willi syndrome such as craniopharyngeomas
  • Down syndrome genetic diseases and
  • Diabetes mellitus type 2 is a condition relating to non-insulin-dependent diabetes mellitus.
  • Non-insulin-dependent diabetes mellitus is a risk factor/secondary disorder in context of the present invention. Diabetes mellitus type 2 results from insulin resistance, a condition in which cells fail to use insulin properly, sometimes combined with an absolute insulin deficiency. This form was previously referred to as non insulin-dependent diabetes mellitus (NIDDM) or "adult-onset diabetes".
  • NIDDM non insulin-dependent diabetes mellitus
  • Non-insulin-dependent diabetes mellitus can be classified in accordance with the ICD-10 version:2010 of the World Health Organization (WHO) as follows:
  • diabetes (mellitus)(nonobese)(obese) :
  • the present invention provides antagonists of SLC38A9. These antagonists can be used as a medicament, i.e. the antagonists of SLC38A9 provided and described herein are for use in medicine (e.g. for use in the therapy/treatment of a disease, in particular a disease associated with mTORCl activation).
  • the terms "medicament” and “pharmaceutical composition” are used interchangeably herein. Accordingly, definitions and explanations provided herein in relation to “pharmaceutical compositions”, apply, mutatis mutandis, to the term “medicament”.
  • treatment means obtaining a desired pharmacological and/or physiological effect.
  • the effect may be prophylactic in terms of completely or partially preventing a disease or symptom thereof and/or may be therapeutic in terms of partially or completely curing a disease and/or adverse effect attributed to the disease.
  • treatment covers any treatment of a disease in a subject and includes: (a) preventing a disease related in a subject which may be predisposed to the disease; (b) inhibiting the disease, i.e. arresting its development; or (c) relieving the disease, i.e. causing regression of the disease.
  • an “individual”, “patient” or “subject” for the purposes of the present invention includes both humans and other animals, particularly mammals, and other organisms. Thus, the methods are applicable to both human therapy and veterinary applications.
  • the "individual”, “patient” or “subject” is a mammal, and most preferably the “individual", “patient” or “subject” is human.
  • antagonist of SLC38A9 means in context of the present invention a compound capable of fully or partially preventing or reducing the physiologic activity and/or expression level of SLC38A9.
  • antagonist or “inhibitor” are used interchangeably herein. It is envisaged herein that the antagonist of SLC38A9 is a selective antagonist of SLC38A9. In the context of the present invention said antagonist may, therefore, prevent, reduce, inhibit or inactivate the physiological activity of SLC38A9 e.g. upon binding of said compound/substance (i.e. antagonist/inhibitor) to said SLC38A9.
  • the term "antagonist” also encompasses competitive antagonists, (reversible) non-competitive antagonists or irreversible antagonist, as described, inter alia, in Mutschler, "Arzneistoff Eckpell” (1986),ticianliche Verlagsgesellschaft mbH, Stuttgart, Germany. Such an inhibition can be measured by determining substrate turnover.
  • an "antagonist” or “inhibitor” of SLC38A9 may also be capable of preventing the function of a SLC38A9 by preventing/reducing the expression of the nucleic acid molecule encoding for said SLC38A9.
  • an antagonist/inhibitor of SLC38A9 may lead to a decreased expression level of SLC38A9 (e.g. decreased level of SLC38A9 mRNA and/or of SLC38A9 protein); this may be reflected in a decreased SLC38A9 activity.
  • the decreased activity and/or expression level can be measured/detected by known methods which are also described herein.
  • an “antagonist/inhibitor of SLC38A9” may, for example, interfere with transcription of (an) SLC38A9 gene(s), processing (e.g. splicing, export from the nucleus and the like) of the gene product(s) (e.g. unspliced or partially spliced mRNA) and/or translation of the gene product (e.g. mature mRNA).
  • the "antagonist/inhibitor of SLC38A9” may also interfere with further modification (like glycosylation or phosphorylation) of the polypeptide/protein encoded by the SLC38A9 gene(s) and thus completely or partially inhibit the activity of the a SLC38A9 protein(s) as described herein above.
  • the "antagonist/inhibitor of a SLC38A9” may interfere with interactions of the SLC38A9 protein(s) with other proteins (thus, for example, interfering with the activity of complexes involving SLC38A9 protein(s)) or, in general, with its synthesis, e.g. by interfering with upstream steps of SLC38A9 expression or with signalling pathways in which the SLC38A9 is involved.
  • such antagonists may, for example, be denoted “sequestering antagonists” or “signalling antagonists”.
  • the herein described SLC38A9 antagonist/inhibitor will, accordingly, lead to a decrease or reduction of SLC38A9 expression level and/or activity, and thereby reduce its contribution to the development, proliferation or progress of a disease associated with mTORC 1 activation as defined herein.
  • the antagonist(s) may be (a) (small) binding molecule, (a) small molecule drug(s), siRNA, shRNA, miRNA, dsRNA, stRNA or antisense molecules.
  • the binding molecule(s) can be (an) aptamer(s) and/or (an) intramer(s). Also envisaged are extracellular binding-partners.
  • the binding molecule antagonizing SLC38A9 specifically binds to SLC38A9, particularly to the SLC38A9 protein (or a part thereof, like the cytoplasmic region or portions or conservative domains/motivs thereof) as defined herein.
  • aptamers/intramers targeting the N-terminal cytoplasmic region as defined here can be used herein as antagonists of SLC38A9.
  • aptamers/intramers to be used herein can specifically target or bind to the following N-terminal cytoplasmic region of SLC38A9 as shown in SEQ ID NOs: 22, 54, 56, 58, 60, or 62.
  • aptamers/intramers to be used herein can specifically target or bind to the following transmembrane region of SLC38A9 as shown in SEQ ID NOs: 68, 70, 72 or 74.
  • the aptamers/intramers can specifically target/bind to (functional) fragments or (functional) derivatives of the SLC38A9 proteins as defined herein, for example also to polypeptides having at least 70 % or more identity to herein provided SLC38A9 protein(s).
  • the present invention relates to the use of these aptamers/intramers in particular in the therapeutic methods of the present invention.
  • (A) small molecule drug(s) to be used herein as antagonist of SLC38A9 refers to an (organic) low molecular weight ( ⁇ 900 Daltons) compound. Small molecules can help to regulate a biological process and have usually a size in the order of 10 9 m. Antagonists to be used herein, like small molecules (drugs), can, for example, be identified by screening compound libraries, for example Enamine, Chembridge or Prestwick chemical libraries.
  • exemplary antagonists of SLC38A9 are siRNA, shRNA, miRNA, dsRNA, stRNA, or antisense molecule targets a nucleic acid molecule having a sequence encoding SLC38A9.
  • the nucleic acid molecule having a sequence encoding SLC38A9 is especially mRNA as defined herein.
  • the present invention relates to and provides in particular an siRNA or shRNA specifically targeting the nucleic acid encoding the SLC38A9 protein(s), whereby the nucleic is especially mRNA as defined herein below.
  • Antagonist(s)/inhibitor(s) of SLC38A9 which are nucleic acids, such as siRNAs, shRNAs, antisense molecules and the like can readily be prepared by known techniques using, for example, the following target sequences.
  • siRNAs, shRNAs and the like to be employed herein can comprise or consist of an RNA sequence corresponding to one of the target sequences further described below.
  • RNA sequence corresponding to means in this context that the RNA sequence is identical to one of the target sequences below, if necessary with the exception that the tymidine (T) residues of the target sequence is replaced by a uracil (U) residue. It is understood that siRNAs, shRNAs usually comprise one strand that is (partially) complementary to the target sequence.
  • the siRNA can consist of or comprise a nucleic acid molecule comprising at least eight (or ten) contiguous bases.
  • the siRNA, shRNA and the like can comprise at least eight (or ten) contiguous bases of an RNA sequence corresponding to one of the target sequences below as defined above.
  • the siRNA, shRNA and the like can consist or comprise of ten contiguous bases of an RNA sequence corresponding to one of the target sequences below as defined above.
  • an antagonizing siRNA to be used herein can comprise a nucleic acid molecule comprising at least eight contiguous bases having a sequence as shown in the sequence of SEQ ID NO: 5, 6, 7 or 8.
  • the siRNA can further comprise at least one base at the 5' end and/or at least one base at the 3' end.
  • the siRNA can consist of a molecule as shown in SEQ ID NO: 5, 6, 7 or 8 and/or an RNA molecule (partially) complementary to the sequence as shown in SEQ ID NO: 5, 6, 7 or 8.
  • the siRNA consists of a molecule as shown in SEQ ID NO: 5, 6, 7 or 8 and an RNA molecule (partially) complementary to the sequence as shown in SEQ ID NO: 5, 6, 7 or 8.
  • RNA molecule complementary to the sequence as shown in SEQ ID NO: 5, 6, 7 or 8 are as follows:
  • SiRNA sequence 1 (sense sequence): AC ACUG AAGG AUAC GGUAA (SEQ ID NO: 63) -> target nt 530-548 of human SLC38A9 mRNA (NMJ73514.3)
  • SiRNA sequence 2 GAUCCUGGACCUAUGAAUA (SEQ ID NO: 64) -> target nt 262-280 of human SLC38A9 mRNA (NM_173514.3)
  • SiRNA sequence 3 GAAGAGUGCUAUGUGUAUA (SEQ ID NO: 65) -> target nt 478-496 of human SLC38A9 mRNA (NMJ73514.3)
  • SiRNA sequence 4 CAUGUCAUUCAGAGGGUUA (SEQ ID NO: 66) -> target nt 355-373 of human SLC38A9 mRNA (NMJ73514.3)
  • a preferred target sequence of the nucleic acids antagonists as defined above can be selected from the group consisting of
  • nucleic acid hybridizing under stringent conditions to the complementary strand of the nucleic acid as defined in (a) or (b);
  • nucleic acid comprising a nucleotide sequence with at least 70 % identity to the nucleotide sequence of the nucleic acids of any one of (a) to (c);
  • nucleic acid comprising a nucleotide sequence which is degenerate as a result of the genetic code to the nucleotide sequence of a nucleic acid of any one of (a) to (d).
  • target sequences are shown in SEQ ID NO. 63, SEQ ID NO. 64, SEQ ID NO. 65, or SEQ ID NO. 66. These target sequences correspond to nt 530-548 of human SLC38A9 mRNA (NMJ73514.3) , nt 262-280 of human SLC38A9 mRNA (NMJ73514.3) , target nt 478-496 of human SLC38A9 mRNA (NMJ73514.3) , and nt 355- 373 of human SLC38A9 mRNA (NM_173514.3), respectively. These sequences represent target sequence of the nucleic acids antagonists as defined above (e.g.
  • siRNA or shRNA and the like preferably of siRNA.
  • An exemplary SLC38A9 mRNA sequence is shwon in SEq ID NO: 4, so that the above target sequences and corresponding target sequences in variants or isoforms of that specific sequence can easily be identified.
  • siRNA can be used alone or in combination as antagonists of SLC38A9 in accordance with the present invention.
  • siRNA are of 19 to 21 nt (or in case of a complex of sense and antisense strand of 19 to 21 bp).
  • bases from 2 to 8 (seed region) of the siRNA i.e. in this context of the antisense strand
  • the shRNA used and provided in the experiments has the following full length sequence:
  • the mature antisense sequence of the shRNA used and provided in the experiments is: ATATAGAACTGTTGTCAAGGC (SEQ ID NO: 114).
  • SEQ ID NO: 113 and 114 show DNA sequences corresponding to the RNA sequence of the shRNA as shown in SEQ ID NO. 9 and 10, respectively.
  • the corresponding sense target sequence is: GCCTTGACAACAGTTCTATAT (SEQ ID NO: 11). This corresponds to nt 1931-1951 of human SLC38A9 niRNA (NM 173514.3).
  • the RNA sequence corresponds to the sequence shown in SEQ ID NO: 11 with the exception that the thymidine residues are replaced by uracil residues. Accordingly, these sequences represent target sequence of the nucleic acids antagonists as defined above (e.g. siRNA or and the like, preferably of shRNA).
  • the shRNA can comprise (or consist of) a nucleic acid molecule comprising (or consisting of) (at least eight contiguous nucleotides having) a sequence as shown in the sequence of SEQ ID NO: 9 or 10.
  • the shRNA provided and to be used herein consists of a nucleic acid sequence as shown in SEQ ID NO: 9.
  • the mature antisense sequence of the shRNA to be used and provided consists of a nucleic acid sequence as shown in SEQ ID NO: 10.
  • the inhibitor of SLC38A9 may be administered as a single agent (i.e. in form of a monotherapy) or in form of a combination therapy, for example, conventional therapies like chemo- or radiotherapy for cancers, diet for obesity and methformin or insulin for diabetes type 2.
  • the pharmaceutical composition will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient, the site of delivery of the pharmaceutical composition, the method of administration, the scheduling of administration, and other factors known to practitioners.
  • the "effective amount" of the pharmaceutical composition for purposes herein is thus determined by such considerations.
  • the effective amount of pharmaceutical composition administered to an individual will, inter alia, depend on the nature of the compound.
  • the total (pharmaceutically) effective amount of the inhibitor in the pharmaceutical composition administered orally per dose will be in the range of about 50 mg inhibitor per day to 1000 mg inhibitor per day of patient, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 50 mg inhibitor per day, and most preferably for humans between about 50mg and 600 mg inhibitor per day.
  • an inhibitor may be administered at a dose of 15 mg/kg body weigth per day. If given continuously, the inhibitor is typically administered at a dose rate of about 50 mg per day to about 600 mg per day.
  • An intravenous bag solution may also be employed.
  • the length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect.
  • the particular amounts may be determined by conventional tests which are well known to the person skilled in the art.
  • the length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect.
  • the particular amounts may be determined by conventional tests which are well known to the person skilled in the art.
  • compositions may, inter alia, comprise an administration twice daily, every day, every other day, every third day, every forth day, every fifth day, once a week, once every second week, once every third week, once every month, etc.
  • the total pharmaceutically effective amount of pharmaceutical composition administered parenterally per dose will be in the range of about 1 ⁇ g protein /kg/day to 15 mg protein /kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01 mg protein /kg/day, and most preferably for humans between about 0.01 and 1 mg protein /kg/day.
  • the pharmaceutical composition is typically administered at a dose rate of about 1 ⁇ g/kg/hour to about 50 ⁇ g/kg/hour, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed.
  • the length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect. The particular amounts may be determined by conventional tests which are well known to the person skilled in the art.
  • compositions of the invention may be administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, drops or transdermal patch), bucally, or as an oral or nasal spray.
  • Pharmaceutical compositions of the invention preferably comprise a pharmaceutically acceptable carrier.
  • pharmaceutically acceptable carrier is meant a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.
  • parenteral refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.
  • sustained-release compositions include semi-permeable polymer matrices in the form of shaped articles, e.g., films, or mirocapsules.
  • Sustained-release matrices include polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman, U. et al, Biopolymers 22:547-556 (1983)), poly (2-hydroxyethyl methacrylate) (R. Langer et al, J. Biomed. Mater. Res. 15: 167-277 (1981), and R.
  • Sustained release pharmaceutical composition also include liposomally entrapped compound. Liposomes containing the pharmaceutical composition are prepared by methods known per se: DE 3,218,121; Epstein et al, Proc. Natl. Acad. Sci. (USA) 82:3688-3692 (1985); Hwang et al, Proc. Natl. Acad. Sci.
  • the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal therapy.
  • the pharmaceutical composition is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is nontoxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation.
  • a pharmaceutically acceptable carrier i.e., one that is nontoxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation.
  • the formulations are prepared by contacting the components of the pharmaceutical composition uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation.
  • the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.
  • the carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability.
  • Such materials are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) (poly)peptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.
  • buffers such as phosphate
  • the components of the pharmaceutical composition to be used for therapeutic administration must be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes).
  • Therapeutic components of the pharmaceutical composition generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.
  • the components of the pharmaceutical composition ordinarily will be stored in unit or multi- dose containers, for example, sealed ampoules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution.
  • a lyophilized formulation 10-ml vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous solution, and the resulting mixture is lyophilized.
  • the infusion solution is prepared by reconstituting the lyophilized compound(s) using bacteriostatic Water- for-Injection.
  • Inhibitors for use in accordance with the present invention are described and provided herein. Also the use of inhibitors yet to be generated or known compounds to be tested for their inhibiting activity is envisaged in context of the present invention.
  • the present invention provides a method for assessing the activity of a candidate molecule suspected of being an antagonist of SLC38A9 as defined and provided herein comprising the steps of:
  • a decrease of the SLC38A9 activity can indicate the capacity of the selected molecule to antagonise mTORC 1. Also a decrease in the (expression) level can indicate useful inhibitors of SLC38A9. Accordingly, the term "activity" above can comprise and relate to the "expression level” and vice versa.
  • the present invention relates to a method for assessing the (expression) level of a candidate molecule suspected of being an antagonist of SLC38A9 as defined and provided herein comprising the steps of:
  • a decrease of the SLC38A9 (expression) level can indicate the capacity of the selected molecule to antagonise mTORCl .
  • the SLC38A9 can be any of the SLC38A9 proteins/polypeptides as defined herein above or any of the nucleic acids (particularly mR As) as defined herein, which encode the SLC38A9 proteins/polypeptides.
  • the following exemplary assays can be used in the determination that a candidate molecule is indeed an antagonist of SLC38A9 to be used in accordance with the present invention: assays monitoring transport activities using recombinant SLC38A9 protein and inserted into liposomes to obtain proteoliposomes monitoring transport of amino acids (either radioactive or detected by alternative methods), assays using microinjection in Xenopus oocytes to express SLC38A9 and monitoring transport as above, assays monitoring physical engagement of SLC38A9 using biophysical methods, such as surface plasmon resonance, NMR, alphascreen, fluorescence interference.
  • biophysical methods such as surface plasmon resonance, NMR, alphascreen, fluorescence interference.
  • the following assay can be used to identify antagonists of SLC38A9 (like SLC38A9 activity/ function): 1. In vitro proteoliposome transport assay
  • An in vitro proteoliposome transport assay used to determine SLC38A9 ability to transport amino acids can be used for screening of candidate molecules able to compete with transport of radio- or fluorescently- labelled amino acids.
  • Such assays are known and disclosed in the art, inter alia, in Scalise M, Pochini L, Giangregorio N, Tonazzi A, Indiveri C. Proteoliposomes as tool for assaying membrane transporter functions and interactions with xenobiotics.Pharmaceutics. 2013 Sep 18;5(3):472-97. doi: 10.3390/pharmaceutics5030472, incorporated herein by reference)
  • a corresponding proteoliposome transport assay is shown in the appended example (see Figure 3D) and described in the corresponding method section. This transport assay is used to test candidate molecules. Candidate molecules are screened for the ability to inhibit amino acid transport, for example by competing or inhibiting transport of labelled glutamine.
  • SLC38A9 wildtype or mutant of lysosomal targeting sequences in SLC38A9 can be used to localize the transporter to plasma membrane of human cell lines and screen for inhibitor of its transport activity similarly as described in Wetli, H.A., P.D. Buckett, and M. Wessling-Resnick, Small-molecule screening identifies the selanazal drug ebselen as a potent inhibitor of DMT 1 -mediated iron uptake. Chem Biol, 2006. 13(9): p. 965- 72, which is incorporated herein by reference).
  • Candidate molecules can be screened for the ability to influence uptake of labeled amino acids or unlabeled amino acids using metabolomic.
  • Cell lines stably expressing wild type SLC38A9 are generated. High expressing clones are be selected and tested for plasma membrane localization. In parallel, potential lysosomal localization motifs, such as dileucine motifs present in the C terminal region of SLC38A9 or glycosylation site, will be mutagenized singularly or in combination. Localisation of mutant constructs will be assessed by transient transfection in HEK293T cells followed by immunostaining as described in the method section related to Figure II and Figure 7. Construct showing plasma membrane localization is selected for verification of retained transport activity in the proteoliposome system and for generation of stable expression in HEK293T, HeLa or other suitable cell lines.
  • SLC38A9-dependent transport of labeled amino acids in these stable expressing cell lines is assessed and candidate molecules are tested for their ability to reduce import of labeled or unlabelled amino acid.
  • SLC38A9 cells is pretreated with a candidate molecule or vehicle control and then incubated with amino acids.
  • labeled amino acids radio- , fluorescenty-labelled or similar
  • cells are washed and intracellular accumulation is measured and compared to cells treated with vehicle control.
  • unlabeled amino acids their extracellular and intracellular concentration concentration is measured by metabolomic.
  • Recombinant Ragulator/RAG GTPase proteins and the N terminal region of SLC38A9 are produced and used to set up an in vitro binding assay allowing to monitor direct interaction between Ragulator/RAG GTPase protein and SLC38A9.
  • in vitro binding assay such as AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay Screen) or ELISA (Enzyme -Linked Immunosorbent Assay) are used to screen for candidate molecules able to inhibit binding.
  • AlphaScreen Ampliclified Luminescent Proximity Homogeneous Assay Screen
  • ELISA Enzyme -Linked Immunosorbent Assay
  • Interaction is detected by AlphaScreen upon addition of streptavidin-coated donor beads and anti-FLAG-coated acceptor beads (AlphaScreen FLAG detection kit, Perkin Elmer). Candidate molecules are then tested for the ability to inhibit the interaction using this assay.
  • the nucleic acid sequence encoding for orthologous/homologous/identical (and thus related) sequences of the herein provided SLC38A9 is at least 70% homologous/identical to the nucleic acid sequence as, inter alia, shown in SEQ ID NO. 1, 2, 4, 12, 13, 15, 16, 18, 19, 21, 53, 55, 57, 59, 61, 67, 69, 71 or 73 (preferably SEQ ID NO. 1, 2 or 4).
  • the nucleic acid sequence encoding orthologous/homologous/identical (and thus related) sequences of the herein provided SLC38A9 is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%), 95%), 96%), 97%o or 98%> homologous/identical to the nucleic acid sequence as, inter alia, shown in SEQ ID NOs. 1, 2, 4, 12, 13, 15, 16, 18 19, 21, 53, 55, 57, 59, 61, 67, 69, 71 or 73 (preferably SEQ ID NO. 1, 2 or 4), wherein the higher values are preferred.
  • the nucleic acid sequence encoding for orthologous/homologous/identical (and thus related) sequences of the herein provided SLC38A9 is at least 99%> homologous/identical to the nucleic acid sequence as, inter alia, shown in SEQ ID NOs. 1, 2, 4, 12, 13, 15, 16, 18, 19, 21, 53, 55, 57, 59, 61, 67, 69, 71 or 73 (preferably SEQ ID NO. 1, 2 or 4).
  • the term "orthologous protein” or “orthologous gene” as used herein refers to proteins and genes, respectively, in different species that are similar to each other because they originated from a common ancestor.
  • Hybridization assays for the characterization of orthologs or other related sequences of known nucleic acid sequences are well known in the art; see e.g. Sambrook, Russell “Molecular Cloning, A Laboratory Manual”, Cold Spring Harbor Laboratory, N.Y. (2001); Ausubel, “Current Protocols in Molecular Biology”, Green Publishing Associates and Wiley Interscience, N.Y. (1989).
  • hybridization or “hybridizes” as used herein may relate to hybridizations under stringent or non-stringent conditions. If not further specified, the conditions are preferably non-stringent. Said hybridization conditions may be established according to conventional protocols described, e.g., in Sambrook (2001) loc. cit.; Ausubel (1989) loc. cit, or Higgins and Hames (Eds.) "Nucleic acid hybridization, a practical approach" IRL Press Oxford, Washington DC, (1985). The setting of conditions is well within the skill of the artisan and can be determined according to protocols described in the art.
  • the detection of only specifically hybridizing sequences will usually require stringent hybridization and washing conditions such as, for example, the highly stringent hybridization conditions of 0.1 x SSC, 0.1% SDS at 65°C or 2 x SSC, 60°C, 0.1 % SDS.
  • Low stringent hybridization conditions for the detection of homologous or not exactly complementary sequences may, for example, be set at 6 x SSC, 1%> SDS at 65°C.
  • the length of the probe and the composition of the nucleic acid to be determined constitute further parameters of the hybridization conditions.
  • the terms "homology” or “percent homology” or “identical” or “percent identity” or “percentage identity” or “sequence identity” in the context of two or more nucleic acid sequences refers to two or more sequences or subsequences that are the same, or that have a specified percentage of nucleotides that are the same (preferably at least 70% identity, more preferably at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%), 96%o, 97%) or 98%> identity, most preferably at least 99% identity), when compared and aligned for maximum correspondence over a window of comparison (preferably over the full length), or over a designated region as measured using a sequence comparison algorithm as known in the art, or by manual alignment and visual inspection.
  • Sequences having, for example, 75% to 90%> or greater sequence identity may be considered to be substantially identical. Such a definition also applies to the complement of a test sequence. Preferably the described identity exists over a region that is at least about 15 to 25 nucleotides in length, more preferably, over a region that is at least about 50 to 100 nucleotides in length and most preferably, over a region that is at least about 800 to 1200 nucleotides in length. Those having skill in the art will know how to determine percent identity between/among sequences using, for example, algorithms such as those based on CLUSTALW computer program (Thompson Nucl. Acids Res. 2 (1994), 4673-4680) or FASTDB (Brutlag Comp. App. Biosci. 6 (1990), 237-245), as known in the art.
  • CLUSTALW computer program Thimpson Nucl. Acids Res. 2 (1994), 4673-4680
  • FASTDB Brutlag Comp. App. Biosci
  • nucleotide residue in a nucleic acid sequence corresponds to a certain position in the nucleotide sequence of e.g. SEQ ID NOs. 1, 2, 4, 12, 13, 15, 16, 18, 19, 21, 53, 55, 57, 59, 61, 67, 69, 71 or 73 (preferably SEQ ID NO. 1, 2 or 4), respectively
  • the skilled person can use means and methods well-known in the art, e.g., alignments, either manually or by using computer programs such as those mentioned herein.
  • BLAST 2.0 which stands for Basic Local Alignment Search Tool BLAST (Altschul (1997), loc. cit.; Altschul (1993), loc. cit.; Altschul (1990), loc.
  • HSP High-scoring Segment Pair
  • the parameter E establishes the statistically significant threshold for reporting database sequence matches.
  • E is interpreted as the upper bound of the expected frequency of chance occurrence of an HSP (or set of HSPs) within the context of the entire database search. Any database sequence whose match satisfies E is reported in the program output.
  • amino acid sequences of members SLC38A9, in particular an amino acid sequence as depicted in SEQ ID NO: 3 (SLC38A9 isoform 1), SEQ ID NO: 14 (SLC38A9 isoform 2), SEQ ID NO: 17 (SLC38A9 isoform 3), SEQ ID NO: 20 (SLC38A9 isoform 4), or, in relation to the cytoplasmic region, SEQ ID NOs.
  • polypeptide to be used in accordance with the present invention has at least 70 % homo logy/identity to a SLC38A9 protein/polypeptide having the amino acid sequence as, for example, depicted in SEQ ID NO: 3, 14, 17, 20. 22, 54, 56, 58, 60, 62, 68, 70, 72 or 74, (preferably SEQ ID NO: 3).
  • the polypeptide has at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% or 98% homology/identity to a SLC38A9 protein/polypeptide having the amino acid sequence as, for example, depicted in SEQ ID NO: 3, 14, 17, 20, 22, 54, 56, 58, 60, 62, 68, 70, 72 or 74, (preferably SEQ ID NO: 3), respectively, wherein the higher values are preferred.
  • the polypeptide has at least 99% homology to a SLC38A9 protein/polypeptide having the amino acid sequence as, for example, depicted in SEQ ID NO: 3, 14, 17, 20, 22, 54, 56, 58, 60, 62, 68, 70, 72 or 74, (preferably SEQ ID NO: 3), respectively.
  • complement For sequence 5 'AGTGAAGT3 ', the complement is 3 CACTTCA5 ', the reverse complement is 3 'ACTTCACT5 ' and the reverse sequence is 5'TGAAGTGA3 ' .
  • transgenic cell(s), transgenic) tissue(s) or (transgenic) non-human animal(s) to be used and provided herein.
  • These cell(s), tissue(s) or (animals) are, for example, useful in the herein provided screening assays, like assays for assessing the activity of candidate molecules suspected of being an antagonist of SLC38A9.
  • transgenic cell(s), transgenic tissue(s) or (a) transgenic non-human animal(s) having or comprising the nucleic acid as described and explained herein (or a vector comprising same), e.g. a nucleic acid comprising a sequence encoding SLC38A9 as defined herein are useful for such purpuses.
  • transgenic cell(s), (transgenic) tissue(s) or (a) (transgenic) non- human animal(s) can be used for screening and/or validation of a medicament for the treatment of a disease associated with mTORCl activation.
  • the term "cell” as used in this context may also comprise a plurality of cells as well as cells comprised in a tissue.
  • the cell to be used in the screening or validation method may be obtained from samples from a (transgenic) non-human animal or human suffering from a disease associated with mTORCl activation.
  • the cell e.g. a tumor cell and the like
  • patient samples e.g. biopsies
  • the cell may be a human cell.
  • such a cell to be used in the present screening or validation methods may be comprised in a tissue or tissue sample, like in a sample biopsy.
  • the used non-human animal or cell may be transgenic or non transgenic.
  • Transgenic in this context particularly means that SLC38A9 as described or defined herein is (over-) expressed and/or that the activity of SLC38A9 (protein) is present (or increased).
  • a preferred (transgenic) non-human animal or (transgenic) cell in context of the invention suffers from a disease associated with mTORCl activation.
  • transgenic non-human animal or “transgenic cell” as used herein refers to a non- human animal or cell, not being a human, that comprises genetic material different from the genetic material of a corresponding wild-type animal/cell.
  • Genetic material in this context may be any kind of a nucleic acid molecule, or analogues thereof, for example a nucleic acid molecule, or analogues thereof as defined herein.
  • “Different” in this context means additional or fewer genetic material with respect to the genome of the wild-type animal/cell and/or rearranged genetic material, i.e. genetic material present at a different locus of the genome with respect to the genome of the wild-type animal/cell.
  • the (transgenic) non-human animal or (transgenic) cell is or is derived from a mammal.
  • Non-limiting examples of the (transgenic) non-human animal or derived (transgenic) cell are selected from the group consisting of a mouse, a rat, a rabbit, and a guinea pig.
  • the present invention also relates to a vector comprising the nucleic acid molecule of the present invention.
  • plasmids are known to those skilled in molecular biology, the choice of which would depend on the function desired and include plasmids, cosmids, viruses, bacteriophages and other vectors used conventionally in genetic engineering. Methods which are well known to those skilled in the art can be used to construct various plasmids and vectors; see, for example, the techniques described in Sambrook et al. (loc cit.) and Ausubel, Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N.Y. (1989), (1994). Alternatively, the polynucleotides and vectors of the invention can be reconstituted into liposomes for delivery to target cells.
  • a cloning vector was used to isolate individual sequences of DNA. Relevant sequences can be transferred into expression vectors where expression of a particular polypeptide is required.
  • Typical cloning vectors include pBluescript SK, pGEM, pUC9, pBR322 and pGBT9.
  • Typical expression vectors include pTRE, pCAL-n-EK, pESP-1, pOP13CAT.
  • said vector comprises a nucleic acid sequence which is a regulatory sequence operably linked to said nucleic acid sequence defined herein.
  • control sequence refers to DNA sequences, which are necessary to effect the expression of coding sequences to which they are ligated. The nature of such control sequences differs depending upon the host organism. In prokaryotes, control sequences generally include promoter, ribosomal binding site, and terminators. In eukaryotes generally control sequences include promoters, terminators and, in some instances, enhancers, transactivators or transcription factors. The term “control sequence” is intended to include, at a minimum, all components the presence of which are necessary for expression, and may also include additional advantageous components.
  • operably linked refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner.
  • a control sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences.
  • the control sequence is a promoter, it is obvious for a skilled person that double-stranded nucleic acid is preferably used.
  • the recited vector is preferably an expression vector.
  • An "expression vector” is a construct that can be used to transform a selected host and provides for expression of a coding sequence in the selected host.
  • Expression vectors can for instance be cloning vectors, binary vectors or integrating vectors.
  • Expression comprises transcription of the nucleic acid molecule preferably into a translatable mRNA.
  • Regulatory elements ensuring expression in prokaryotes and/or eukaryotic cells are well known to those skilled in the art. In the case of eukaryotic cells they comprise normally promoters ensuring initiation of transcription and optionally poly-A signals ensuring termination of transcription and stabilization of the transcript.
  • Possible regulatory elements permitting expression in prokaryotic host cells comprise, e.g., the P L , lac, trp or tac promoter in E. coli, and examples of regulatory elements permitting expression in eukaryotic host cells are the AOX1 or GAL1 promoter in yeast or the CMV-, SV40-, RSV-promoter (Rous sarcoma virus), CMV-enhancer, SV40-enhancer or a globin intron in mammalian and other animal cells.
  • Beside elements which are responsible for the initiation of transcription such regulatory elements may also comprise transcription termination signals, such as the SV40-poly-A site or the tk-poly-A site, downstream of the polynucleotide.
  • transcription termination signals such as the SV40-poly-A site or the tk-poly-A site, downstream of the polynucleotide.
  • leader sequences capable of directing the polypeptide to a cellular compartment or secreting it into the medium may be added to the coding sequence of the recited nucleic acid sequence and are well known in the art; see also the appended Examples.
  • the leader sequence(s) is (are) assembled in appropriate phase with translation, initiation and termination sequences, and preferably, a leader sequence capable of directing secretion of translated protein, or a portion thereof, into the periplasmic space or extracellular medium.
  • the heterologous sequence can encode a fusion protein including an N-terminal identification peptide imparting desired characteristics, e.g., stabilization or simplified purification of expressed recombinant product; see supra.
  • suitable expression vectors are known in the art such as Okayama-Berg cDNA expression vector pcDVl (Pharmacia), pCDM8, pRc/CMV, pcDNAl, pcDNA3 (In-vitrogene), pEF-DHFR, pEF-ADA or pEF-neo (Mack et al. PNAS (1995) 92, 7021-7025 and Haut et al. Cancer Immunol Immunother (2001) 50(3), 141-150) or pSPORTl (GIBCO BRL).
  • the expression control sequences will be eukaryotic promoter systems in vectors capable of transforming of transfecting eukaryotic host cells, but control sequences for prokaryotic hosts may also be used.
  • the vector Once the vector has been incorporated into the appropriate host, the host is maintained under conditions suitable for high level expression of the nucleotide sequences, and as desired, the collection and purification of the polypeptide of the invention may follow; see, e.g., the appended examples.
  • An alternative expression system which can be used to express a cell cycle interacting protein is an insect system.
  • Autographa californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in Spodoptera frugiperda cells or in Trichoplusia larvae.
  • the coding sequence of a recited nucleic acid molecule may be cloned into a nonessential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of said coding sequence will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein coat. The recombinant viruses are then used to infect S.
  • frugiperda cells or Trichoplusia larvae in which the protein of the invention is expressed (Smith, J. Virol. 46 (1983), 584; Engelhard, Proc. Nat. Acad. Sci. USA 91 (1994), 3224-3227).
  • Additional regulatory elements may include transcriptional as well as translational enhancers.
  • the above-described vectors of the invention comprise a selectable and/or scorable marker.
  • Selectable marker genes useful for the selection of transformed cells and, e.g., plant tissue and plants are well known to those skilled in the art and comprise, for example, antimetabolite resistance as the basis of selection for dhfr, which confers resistance to methotrexate (Reiss, Plant Physiol. (Life Sci. Adv.) 13 (1994), 143-149); npt, which confers resistance to the aminoglycosides neomycin, kanamycin and paromycin (Herrera-Estrella, EMBO J. 2 (1983), 987-995) and hygro, which confers resistance to hygromycin (Marsh, Gene 32 (1984), 481- 485).
  • trpB which allows cells to utilize indole in place of tryptophan
  • hisD which allows cells to utilize histinol in place of histidine
  • mannose-6-phosphate isomerase which allows cells to utilize mannose
  • ODC ornithine decarboxylase
  • DFMO ornithine decarboxylase
  • deaminase from Aspergillus terreus which confers resistance to Blasticidin S (Tamura, Biosci. Biotechnol. Biochem. 59
  • luciferase a gene encoding luciferase (Giacomin, PL Sci. 116
  • nucleic acid molecule can be used alone or as part of a vector to express the polypeptide of the invention in cells, for, e.g., purification but also for gene therapy purposes.
  • the nucleic acid molecules or vectors containing the DNA sequence(s) encoding any one of the above described polypeptide of the invention is introduced into the cells which in turn produce the polypeptide of interest.
  • Gene therapy which is based on introducing therapeutic genes into cells by ex-vivo or in-vivo techniques is one of the most important applications of gene transfer.
  • Suitable vectors, methods or gene-delivery systems for in-vitro or in-vivo gene therapy are described in the literature and are known to the person skilled in the art; see, e.g., Giordano, Nature Medicine 2 (1996), 534-539; Schaper, Circ. Res. 79 (1996), 911-919; Anderson, Science 256 (1992), 808-813; Verma, Nature 389 (1994), 239; Isner, Lancet 348 (1996), 370-374; Muhlhauser, Circ. Res. 77 (1995), 1077-1086; Onodera, Blood 91 (1998), 30-36; Verma, Gene Ther. 5 (1998), 692-699; Nabel, Ann. N.Y. Acad. Sci.
  • nucleic acid molecules and vectors may be designed for direct introduction or for introduction via liposomes, or viral vectors (e.g., adenoviral, retroviral) into the cell.
  • said cell is a germ line cell, embryonic cell, or egg cell or derived there from, most preferably said cell is a stem cell.
  • An example for an embryonic stem cell can be, inter alia, a stem cell as described in Nagy, Proc. Natl. Acad. Sci. USA 90 (1993), 8424-8428.
  • the invention also provides for a host transformed or transfected with a vector of the invention.
  • Said host may be produced by introducing the above described vector of the invention or the above described nucleic acid molecule of the invention into the host.
  • the presence of at least one vector or at least one nucleic acid molecule in the host may mediate the expression of a gene encoding the above described SLC38A9.
  • the described nucleic acid molecule or vector of the invention, which is introduced in the host may either integrate into the genome of the host or it may be maintained extrachromosomally.
  • the host can be any prokaryote or eukaryotic cell.
  • prokaryote is meant to include all bacteria, which can be transformed or transfected with DNA or RNA molecules for the expression of a protein of the invention.
  • Prokaryotic hosts may include gram negative as well as gram positive bacteria such as, for example, E. coli, S. typhimurium, Serratia marcescens and Bacillus subtilis.
  • eukaryotic is meant to include yeast, higher plant, insect and preferably mammalian cells.
  • the protein encoded by the polynucleotide of the present invention may be glycosylated or may be non- glycosylated.
  • the length of said FLAG-tag is about 4 to 8 amino acids, most preferably 8 amino acids.
  • An above described polynucleotide can be used to transform or transfect the host using any of the techniques commonly known to those of ordinary skill in the art.
  • methods for preparing fused, operably linked genes and expressing them in, e.g., mammalian cells and bacteria are well-known in the art (Sambrook, loc cit.).
  • said the host is a bacterium or an insect, fungal, plant or animal cell.
  • the recited host may be a mammalian cell.
  • host cells comprise CHO cells, COS cells, myeloma cell lines like SP2/0 or NS/0.
  • CHO-cells as hosts.
  • said host cell is a human cell or human cell line, e.g. per.c6 (Kroos, Biotechnol. Prog., 2003, 19: 163-168).
  • the transformed hosts can be grown in fermentors and cultured according to techniques known in the art to achieve optimal cell growth.
  • the polypeptide of the invention can then be isolated from the growth medium, cellular lysates, or cellular membrane fractions.
  • the isolation and purification of the, e.g., microbially expressed polypeptides of the invention may be by any conventional means such as, for example, preparative chromatographic separations and immunological separations such as those involving the use of monoclonal or polyclonal antibodies directed, e.g., against a tag of the polypeptide of the invention or as described in the appended examples.
  • the polypeptide of the invention can be purified according to standard procedures of the art, including ammonium sulfate precipitation, affinity columns, column chromatography, gel electrophoresis and the like; see, Scopes, "Protein Purification", Springer-Verlag, N.Y. (1982). Substantially pure polypeptides of at least about 90 to 95% homogeneity are preferred, and 98 to 99% or more homogeneity are most preferred, for pharmaceutical uses. Once purified, partially or to homogeneity as desired, the polypeptide of the invention may then be used therapeutically (including extracorporeally) or in developing and performing assay procedures. Furthermore, examples for methods for the recovery of the polypeptide of the invention from a culture are described in detail in the appended examples.
  • kits useful for carrying out the methods of the invention comprising a nucleic acid or an antibody capable of detecting the presence of SLC38A9 (like SLC38A9 mRNA or protein) as defined herein. Also envisaged herein is the use of the herein described kit for carrying out the herein provided methods.
  • said kit may comprise (a) compound(s) required for specifically determining the presence of SLC38A9 (like SLC38A9 mRNA or protein) as defined herein.
  • the present invention also relates to the use of (a) compound(s) required for specifically determining the presence of SLC38A9 (like SLC38A9 mRNA or protein) as defined herein for the preparation of a kit for carrying out the methods of this invention.
  • the skilled person knows which compound(s) is (are) required for specifically determining the presence of SLC38A9 (like SLC38A9 mRNA or protein) as defined herein.
  • such compound(s) may be (a) "binding molecule(s)", like, for example, (a) antibody.
  • such compound(s) may be (a) (nucleotide) probe(s), (a) primer(s) (pair(s)), (an) antibody(ies) and/or (an) aptamer(s) specific for SLC38A9 (like SLC38A9 mRNA or protein) as defined herein.
  • Such compounds may also be useful for determining the activity of SLC38A9 (like SLC38A9 mRNA or, primarily SLC38A9 protein) as defined herein.
  • the kit (to be prepared in context) of this invention may be a diagnostic kit and in particular a kit for assaying candidate molecules.
  • the kit (to be prepared in context) of this invention may further comprise or be provided with (an) instruction manual(s).
  • said instruction manual(s) may guide the skilled person (how) to determine the presence of SLC38A9 as defined herein and/or (how) to determine the activity of SLC38A9 as defined herein.
  • Said instruction manual(s) may comprise guidance to use or apply the herein provided methods or uses.
  • the kit (to be prepared in context) of this invention may further comprise substances/chemicals and/or equipment suitable/required for carrying out the methods and uses of this invention.
  • such substances/chemicals and/or equipment are solvents, diluents and/or buffers for stabilizing and/or storing (a) compound(s) required for specifically determining the presence/activity of SLC38A9 as defined herein.
  • An exemplary antibody specifically binding to SLC38A9 that can be used in these kits and screening methods is commercially available from Sigma (HPA043785)).
  • Polyclonal or monoclonal antibodies or other antibodies (derived therefrom) for use in the kits or screening methods provided herein can be routinely prepared using, inter alia, standard immunization protocols; see Ed Harlow, David Lane, (December 1988), Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory; or Ed Harlow, David Lane, (December 1998), Portable Protocols (Using Antibodies): A Laboratory Manual 2 nd edition, Cold Spring Harbor Laboratory.
  • the herein provided SLC38A9 proteins can be used as an antigen in the production of antagonizing antibodies.
  • a protein or polypeptide can be used as antigen, wherein the protein/polypeptide consists of 15 to 25 contiguous amino acids of a SLC38A9 protein as defined herein (e.g. as shown in SEQ ID NO: 3 or related sequences).
  • the protein/polypeptide can consist of 15 to 25 contiguous amino acids of the N- terminal cytoplasmic region of a SLC38A9 protein as defined and provided herein.
  • a fragment of the protein shown in SEQ ID NO: 3 comprising or consisting of 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 amino acids of the protein as shown in SEQ ID NO: 3 can be used as an antigen.
  • fragments of the protein shown in SEQ ID NO: 3 comprising or consisting of 15 to 25 contiguous amino acids of the protein as shown in SEQ ID NO: 3.
  • a fragment of the protein shown in SEQ ID NO: 3 comprising or consisting of 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 contiguous amino acids of the protein as shown in SEQ ID NO: 3 is provided and used herein.
  • the SLC38A9 protein can be produced recombinantly (i.e. produced in appropriate host cells) or synthetic (i.e. chemically synthesized). .
  • Recombinant production of SLC38A9 protein is described herein.
  • recombinant production can be achieved using any one of the molecular cloning and recombinant expression techniques known in the art.
  • a nucleic acid molecule encoding SLC38A9 protein can be introduced into an appropriate host cell, such as a bacterium, a yeast cell (e.g., a Pichia cell), an insect cell or a mammalian cell (e.g., CHO cell).
  • the encoding nucleic acid molecule can be placed in an operable linkage to a promoter capable of effecting the expression of the SLC38A9 protein antigen in the host cell.
  • SLC38A9 protein which is expressed by the host cell, can be readily purified using routine protein purification techniques.
  • the nucleotide sequence as set forth in SEQ ID NO: 1 or 2 or a nucleic acid sequence encoding the SLC38A9 shown in SEQ ID NO: 3 or encoding a fragment thereof, such as a protein consisting of 15 to 25 contiguous amino acids of the protein shown in SEQ ID NO: 3, can be cloned in an expression vector and placed in an operable linkage to a temperature sensitive promoter.
  • the expression vector can be introduced into Escherichia coli and the antigen can be expressed upon heat induction.
  • the cells can be lysed and the inclusion bodies where the antigen accumulates are separated by centrifugation.
  • the recombinant protein in the inclusion bodies is solubilized using SDS or other solubilization agents known in the art such as urea, guanidine hydrochloride, sodium cholate, taurocholate, and sodium deoxycholate.
  • a purified recombinant SLC38A9 protein can be combined with a pharmaceutically acceptable carrier to optimize its use as an antigen.
  • immunization may involve the intraperitoneal or subcutaneous administration of the SLC38A9 protein/polypeptide (and/or fragments, iso forms, homologues and so on) as defined herein to a mammal (e.g. rodents such as mice, rats, hamsters and the like).
  • a mammal e.g. rodents such as mice, rats, hamsters and the like.
  • fragments of the SLC38A9 protein/polypeptide are used, wherein the fragment preferably bears the N-terminal cytoplasmic region of the SLC38A9 protein/polypeptide (or a fragment thereof) as defined herein.
  • antibodies recognizing the SLC38A9 protein/polypeptide may be affinity purified.
  • ELISA is commonly used for screening sera and/or assaying affinity column fractions.
  • Western Blots can be used to demonstrate that the antibody can detect the SLC38A9 protein/polypeptide and to evaluate whether the antibody only recognizes the SLC38A9 protein/polypeptide, or if it cross-reacts with other proteins.
  • a method that uses SLC38A9 ((like the information associated with) the sequence encoding the protein or the amino acid sequence of the protein as defined herein) to derive pharmacological agents antagonising its activity and useful for treating, preventing or ameliorating a disease associated with mTORC 1 activation comprising the administration of an antagonist of SLC38A9 to a subject in need of such a treatment, prevention or amelioration.
  • SLC38A9 (like the information associated with) the sequence encoding the protein or the amino acid sequence of the protein as defined herein) to derive pharmacological agents antagonising its activity and useful for treating, preventing or ameliorating a disease associated with mTORC 1 activation comprising the administration of an antagonist of SLC38A9 to a subject in need of such a treatment, prevention or amelioration.
  • a method for treating, preventing or ameliorating a disease associated with mTORCl activation comprising antagonizing/inhibiting (the activity of) SLC38A9 to a subject in need of such a treatment, prevention or amelioration.
  • the term “consisting essentially of” means that specific further components (or likewise features, integers, steps and the like) can be present, namely those not materially affecting the essential characteristics of the composition, device or method.
  • the term “consisting essentially of (which can be interchangeably used herein with the term “comprising substantially”) allows the presence of other components in the composition, device or method in addition to the mandatory components (or likewise features, integers, steps and the like), provided that the essential characteristics of the device or method are not materially affected by the presence of other components.
  • method refers to manners, means, techniques and procedures for accomplishing a given task including, but not limited to, those manners, means, techniques and procedures either known to, or readily developed from known manners, means, techniques and procedures by practitioners of the chemical, biological and biophysical arts.
  • Baits and interactors of SLC38A9 are shown with spectral counts (left, maximum of biological replicate) and sequence coverage (right, percentage). Empty box: not detected, h, HEK293T cells were transfected with the indicated tagged constructs or empty vector (-).
  • IP Anti-HA immunoprecipitates
  • XT cell extracts
  • Interactors of LAMTOR1, LAMTOR3, LAMTOR4, LAMTOR5, RAGA and RAGC were identified by TAP-LC-MS/MS using GFP TAP as negative control. Proteins filtered using SAINT 35 that interacted with at least five bait proteins were retained. Previously published interactors of the Ragulator complex and RAG GTPases that were also detected are highlighted, b, Tabular view of spectral counts (maximum of biological replicate) and sequence coverage (percentage) of the core Ragulator network and published interactors detected, c HEK293T cells were transfected with the indicated constructs or empty vector (-).
  • Anti-HA immunoprecipitates and cell extracts were analysed by immunoblot with the indicated antibodies, d and e, HEK293T cells were transfected with the indicated tagged SLC38A9 constructs or empty vector (-). Anti-HA immunoprecipitates and cell extracts were analysed by immunoblot with the indicated antibodies. Deletion constructs are labelled with the number of the encoded amino acids (d) and point mutants with the amino acid motif substituted to alanine (e).
  • HEK293T cells were transfected with the indicated tagged RAGA (f) or RAGB (g) and RAGC constructs or empty vector (-).
  • Anti-HA immunoprecipitates and cell extracts were treated with PNGase and analysed by immunoblot with the indicated antibodies. Mutations are the following: RAGA: Q66L and T21N; RAGB: Q99L and T54N; RAGC: S75N and Q120N
  • HEK293T cells transduced with lentivirus-encoded shRNA against SLC38A9 or GFP were starved for 50 min in medium without amino acids and serum and then stimulated with amino acids (a) or cycloheximide (b, 25 ⁇ g/ml) for 10 or 20 min.
  • Cell lysates were analysed by immunoblot with antibodies against phosphorylated threonine 389 S6 kinase, phosphorylated S6, phosphorylated ULK1 and total S6 kinase, c, HEK293T were transfected with the indicated siRNA. After 72h, cells were treated as in a.d, HeLa were transfected with the indicated siRNA.
  • a Table of SLCs belonging to amino acid transporter families robustly expressed in HEK293 and K562 cells as monitored by RNAseq. SLC members of amino acid transporter-containing families 16 and expressed (FPKM>0.5) in both cell lines were ranked according to their expression level. The number of PubMed entries was obtained by querying the GeneSymbol.
  • b Expression of members of the SLC32, SLC36 and SLC38 families in HEK293 and K562 cells
  • c Cell size measurements of HEK293T cells after short-hairpin (shRNA) mediated knockdown against GFP (control, dashed line) or SLC38A9 (solid line), measured by automated microscopy and image analysis.
  • shRNA short-hairpin
  • HEK293T cells were transfected with the tagged SLC38A9 constructs (+) or empty vector (a, c).
  • Cell lysates were prepared and left untreated (Untr.) or incubated 1 hour at 37 °C in presence or absence of PNGase and analysed by immunoblot, ⁇ : SLC38A9; *: non-specific band, c and d depict the effect of boiling the lysates for 5 min at 95 °C after PNGase treatment, e and f Lysates from murine NIH3T3 (e) or Raw 264.7 (f) cells were subjected to immunoprecipitation with the indicated antibodies, treated with PNGase and analysed by immunoblot.
  • HEK293T cells were transfected with a streptavidin-HA tagged SLC38A9 construct.
  • Scale bar 10 ⁇ .
  • SLC38A9 peptides detected in LAMTOR1, 3, 4 and 5 (a) or in SLC38A9 (b) TAP- MS/MS analysis are mapped on SLC38A9 sequence and highlighted in bold. Transmembrane helices are underlined. Potential tryptic cleavage sites are in lower case.
  • Transport was stopped as described in Materials and Methods and calculated by subtracting the radioactivity associated to proteoliposomes reconstituted with the empty vector fraction. Values represent means of specific transport ⁇ s.d. from 3 different experiments, e, Effect of pH on the reconstituted SLC38A9. Reconstitution was performed as described in Materials and Methods except that 20 mM Hepes/Tris at the indicated pH was used. Transport was started by adding 10 ⁇ [ 3 H] -glutamine in 20 mM Hepes/Tris buffer at the indicated pH to proteoliposomes and stopped at 30 min. Results are means of specific transport rate ⁇ s.d. from 3 different experiments f-g HEK293T cells were starved in medium without amino acids and serum for the indicated times. SLC38A9 expression was analysed by quantitative PCR (f) and immunoblot (g). ⁇ : SLC38A9; *: non-specific band
  • the Example illustrates the invention.
  • Sentor is an integral component of the lysosomal amino acid- sensing machinery that controls mTORCl activity and antagonists of Sentor (SLC38A9) are useful in the therapy of diseases associated with mTORCl activity
  • Expression constructs were generated by PCR amplification followed by Gateway cloning (Invitrogen) into pTRACER-CV5-GW or pTO-SII-HA-GW 1 with N-terminal tagging for SLC38A9, SLC38A1, SLC38A2, SLC38A7, SLC36A1, SLC36A4, RAGA, RAGB, RAGC and LAMTOR3 (human and mouse) and C-terminal tagging for LAMTOR1, 4 and 5. Point mutations were introduced by site-directed mutagenesis (Invivogen).
  • HEK293 Flp-In TREx cells that allow doxycycline-dependent transgene expression were from Invitrogen.
  • HEK293 Flp-In TREx, HEK293T, HeLa, K562, NIH3T3 and Raw264.7 cells were kept in RPMI medium (PAA Laboratories) supplemented with 10% (v/v) FBS (Invitrogen) and antibiotics (100 U/ml penicillin and 100 mg/ml streptomycin).
  • Cells were transfected with Polyfect (Qiagen) and used for experiments after 24 hours.
  • lysis cells were resuspended in Nonidet-40 lysis buffer (1% NP-40, 50mM Hepes pH7.4, 250 mM NaCl, 5 mM EDTA, Halt phosphatase inhibitor cocktail (ThermoScientific), one tablet of EDTA-free protease inhibitor (Roche) per 50 ml) on ice for 5 min. Lysates were cleared by centrifugation in a microcentrifuge (13000r.p.m., lOmin, 4C). Proteins were quantified with BCA (Pierce).
  • lysates were precleared on Sepharose6 beads (Sigma) (40 min with rotation, 4 °C) and then incubated either with HA- or V5 -coupled beads (3h with rotation, 4 °C) or with primary antibody and protein G-sepharose (GE healthcare) (14h with rotation, 4 °C). Beads were recovered and washed four times with lysis buffer before analysis by SDS-PAGE and immunoblotting. When required, a mouse anti-rabbit IgG (conformation specific) antibody was used for immunoblot and revealed with an anti-mouse HRP-conjugated antibody to avoid detection of immunoglobulin heavy chains. In case of detection of endogenous SLC38A9, samples were treated with PNGase (NEB, 250U for 30 ul, lh, 37 °C) before SDS-PAGE.
  • shRNA-encoding pLKO.l targeting SLC38A9 (ThermoFisher, TRCN0000151238) or GFP (ThermoFisher, RHS4459) were used.
  • Lentiviruses were produced using second- generation packaging plasmids pMD2-VSVG and pCMV-R8.91.
  • HEK293T cells were co-transfected with packaging plasmids and the shR A-encoding plasmids. Cells were washed 16h after transfection. Virus-containing supernatants were collected 24h after washing, filtered and used for infection. After infection, HEK293T cells were selected with puromycin (4 ⁇ g/ml).
  • HEK293T cells were transfected with HiPerfect (Qiagen) with 60 nM of siRNA pool. After 72h cells were subjected to amino acid stimulation as described.
  • ON-TARGETplus SMARTpool against SLC38A9 L-007337-02-0005, Target sequences: AC ACUG AAGG AUAC GGUAA (SEQ ID NO: 77), G AUC CUGG AC CUAUG A AUA (SEQ ID NO: 78), GAAGAGUGCUAUGUGUAUA (SEQ ID NO: 79), CAUGUCAUUCAGAGGGUUA (SEQ ID NO: 80)), LAMTOR1 (L-020916-02-0010, Target sequences: UCUCCAGGAUAGCUGCUUA (SEQ ID NO: 81), GGCUUAUACAGUACCCUAA (SEQ ID NO: 82), AAGUGAGGGUAGAACCUUU (SEQ ID NO: 83), GUUUGUCACCCUCGAUAAA (L-007337-
  • Flp-in HEK293 T-Rex cell lines inducibly expressing SII-HA-tagged SLC38A9, SLC38A1, SLC38A2, SLC36A1, RAGA, RAGC, GFP or LAMTOR complex subunits were generated as described 2 . Tandem affinity STREP-HA purifications were performed as previously described 3 . In brief, cells were stimulated with doxycycline/tetracycline for 24 h to induce expression of SII-HA-tagged bait proteins. Induction of SII-HA-LAMTOR 3 was combined with 9h starvation in serum free medium.
  • Protein complexes were isolated by TAP using streptavidin agarose followed by elution with biotin, and a second purification step using HA- agarose beads. Proteins were eluted with 100 mM formic acid, neutralized with triethylammonium bicarbonate (TEAB) and digested with trypsin, and the peptides were analysed by LC-MS/MS.
  • TEAB triethylammonium bicarbonate
  • Peak list data were extracted from RAW files using Proteo Wizard (release 3.0.3201 - http at proteowizard.sourceforge.net/) and searched against human SwissProt database version v2013.01_20130110 (37,261 sequences and common contaminants).
  • HEK293T cells were plated on fibronectin-coated glass coverslips and, after 16 hours, induced with doxycycline or transfected. After 24h, cells were washed with PBS, fixed (PBS, 4%) formaldehyde) and permeabilized (PBS, 0.3%> Saposin, 10%> FBS). Slides were incubated with anti-HA (sc-805 Santa Cruz), anti-LAMPl (ab25630 Abeam) or anti-LAMP2 (sc-18822 Santa Cruz) antibodies (1 hour, 25 °C, PBS, 0.3% Saposin, 10% FBS).
  • Colocalization was measured as the percentage of SCL38A9 (green) pixel values above background that are also above background in the LAMP1 or LAMP2 (red) channel.
  • the SLC38A9 and LAMP1 or LAMP2 colocalization was verified to be robust to variations in the background threshold, and also shows up as significant pixel value correlations between the red and green channels.
  • CellProfiler www at cellprofiler.org
  • custom Matlab code written specifically for
  • CellProfiler was used to detect individual nuclei on each image, and iterative machine learning using CellClassifier was applied to detect properly segmented interphase nuclei.
  • Population context measurement code was used to measure the local cell density of each individual cell, and cell size measurements were restricted to sparse cells to avoid local crowding from confounding the measurements.
  • the typical nucleus diameter i.e. the diameter of a circle with the same area as that measured for each nucleus
  • HEK293T cells transduced with shRNA against SLC38A9 or GFP were seeded and counted every 24 h using Casy (Roche).
  • HEK293T cells were washed with PBS and incubated in amino acid-free RPMI for 50 min. Cell were then stimulated for 10 or 20 min by the addition of RPMI containing a two time concentrated solution of amino acids. After stimulation, the final concentration of amino acids in the media was the same as in RPMI.
  • amino acid- starved cells were stimulated by addition of cycloheximide diluted in amino acid-free RPMI at a final concentration of 25 ⁇ g/ml.
  • HeLa cells were stimulated for 10 or 20 min by the addition of RPMI containing a two time concentrated solution of amino acids and insulin (1 uM final concentration, Sigma, 19278).
  • Amino acid-free RPMI medium powder (R8999-04A, US biological) was complemented with sodium bicarbonate and sodium phosphate, dissolved in water, adjusted to pH7.4 and filtered.
  • RPMI containing a two time concentrated solution of amino acids was obtained by complementing amino acid-free RPMI medium with RPMI 1640 amino acids solution (R7131, Sigma), adjusted to pH7.4 and filtered.
  • L-glutamine (59202C, Sigma) was added shortly before usage.
  • GAPDH Fw GAAGGTGAAGGTCGGAGT (SEQ ID NO: 87)
  • GAPDH Rev GAAGATGGTGATGGGATTTC (SEQ ID NO: 88)
  • the human SLC38A9 cDNA was optimized according to E. coli codon usage by GenScript.
  • CAI Codon Adaptation Index
  • the optimized cDNA was then sub- cloned cloned into expression vector (pH6EX3-His 6 -hSLC38A9) 1 .
  • the plasmid was used to transform E. coli Lemo21(DE3)pLysS (NEB). Selection on LB-agar was performed as previously described 7 .
  • 0.1 mM rhamnose was added to modulate R A polymerase expression. After addition of 0.4 mM IPTG cells were grown at 39°C for 2 h. Cells were treated as previously described 7 . The protein patterns of the cell lysate fractions were analyzed by SDS-PAGE.
  • the insoluble cell fraction (about 1.5 mg proteins) from cells expressing SLC38A9 or empty vector trans fected cells, was washed with 100 mM Tris/HCl and resuspended in 100 mM ⁇ - ⁇ , 3.5 M urea, 0.5 % sarkosyl, 200 mM NaCl, 10% glycerol, 20 mM Tris/HCl pH 8.0 and centrifuged at 12,000 g for 10 min at 4 °C.
  • the resulting supernatant (about 1 mL) was applied onto a column (0.5 cm x 2.5) filled with His select nickel affinity gel (Sigma) pre-conditioned with 8 mL of 0.1 % sarkosyl, 200 mM NaCl, 10% glycerol, 10 mM Tris/HCl pH 8.0.
  • the elution was performed with 10 mL of 0.1 %> Ci 2 E 8 , 150 mM NaCl, 10% glycerol, 5 mM DTE, 10 mM Tris/HCl pH 8.0 (washing buffer), 1.4 mL of the same buffer plus 10 mM imidazole; then the purified protein fraction (4-7 ⁇ g protein) was eluted by 1.4 mL of the same buffer plus 50 mM imidazole.
  • the purified fractions from SLC38A9 or empty vector preparation were reconstituted by removing the detergent as previously described 8 with a batch-wise procedure from a mixture of 400 of protein (about 2 ⁇ g protein in 0.1 % Ci 2 E 8 , ⁇ - ⁇ 6 mM, 10% glycerol, 20 mM Tris/HCl pH 8.0, 150 mM NaCl, 50 mM imidazole ), 80 ⁇ , of 10 % d 2 E 8 , 100 ⁇ of 10% egg yolk phospholipids (w/v), 20 mM Hepes/Tris pH 6.5.
  • protein about 2 ⁇ g protein in 0.1 % Ci 2 E 8 , ⁇ - ⁇ 6 mM, 10% glycerol, 20 mM Tris/HCl pH 8.0, 150 mM NaCl, 50 mM imidazole ), 80 ⁇ , of 10 % d 2 E 8 , 100 ⁇ of 10% egg yolk phospholipids (w/v), 20 m
  • proteoliposomes 600 ⁇ , were passed through a Sephadex G-75 column (0.7 cm diameter x 15 cm height) preequilibrated with 20 mM Hepes/Tris pH 6.5. Transport (uptake) measurement was started adding 10 ⁇ [ 3 H]glutamine or other radioactive substrates as indicated (0.5 ⁇ / ⁇ ) to 100 ⁇ , proteoliposomes aliquots at 25°C. Transport was stopped by applying each sample of proteoliposomes on a Sephadex G-75 column (0.6 x 8 cm) to separate the external from the internal radioactivity.
  • proteoliposomes For efflux measurements, aliquots of the same pool of proteoliposomes passed through a Sephadex G-75 column (0.7 cm diameter x 15 cm height) preequilibrated with 20 mM Hepes/Tris pH 6.5 were incubated with external 10 ⁇ [ 3 H]glutamine. After 120 min of loading, proteoliposomes were passed again through a Sephadex G-75 column (0.7 cm diameter x 15 cm height) preequilibrated with 20 mM Hepes/Tris pH 6.5, for removing the residual external (not taken up) radioactivity.
  • His-SLC38A9 was incubated overnight at 37°C in absence or in presence of 1 U thrombin (GE healthcare reconstituted according to the manufacturers in PBS IX Invitrogen). After incubation the different samples were assayed by immunob lotting analysis using anti-His or anti-SLC38A9 antibody. This assay represents the control for the following orientation assay.
  • proteoliposomes 200 ⁇ reconstituted as described in the section " Reconstitution of SLC38A9 in proteoliposomes and transport measurements ", were centrifuged at 108.000 x g for 90 minutes, resuspended in 20 mM Hepes/Tris pH 6.5, incubated overnight at 37°C with 1 U thrombin in the same conditions of the purified protein. After incubation proteoliposomes were dissolved by 2.5% SDS and 0.2M Tris/HCl pH 6.8. immunoblotting analysis was performed as described for the purified protein.
  • Reconstitution was performed as described in the section “Reconstitution of SLC38A9 in proteoliposomes and transport measurements", using buffer (Hepes/Tris) at different pH.
  • Transport (uptake) was started as described in the section “Reconstitution of SLC38A9 in proteoliposomes and transport measurements ", by adding, to proteoliposomes, 10 ⁇ [ 3 H]- glutamine in 20 mM Hepes/Tris buffer at the same pH of the reconstitution mixture and stopped after 30 min, as described in the same section.
  • SLC38A9 was purified as described in the section "Cloning, expression and purification of recombinant human SLC38A9” omitting NaCl from elution buffer (0.1 % Ci 2 E 8 , 10% glycerol, 5 mM DTE, 10 mM Tris/HCl pH 8.0, plus imidazole 50 mM). Reconstitution was performed as described in section “Reconstitution of SLC38A9 in proteoliposomes and transport measurements", in the absence or in the presence of 20 or 50 mM NaCl. Transport (uptake) measurement was performed as described in the same section.
  • SLC38 also known as sodium-coupled neutral amino acid transporter, SNAT
  • SNAT sodium-coupled neutral amino acid transporter
  • D6RDH2_HUMAN; NCBI NP_775785.2) is predicted to encompass eleven transmembrane helices and a 120-residue cytoplasmic N-terminal region.
  • Overexpressed SLC38A9 was detected on SDS-PAGE mainly as a diffused band migrating higher than the expected size, suggesting postranslational modification, possibly glycosylation.
  • PNGase F treatment with peptide -N-glycosidase (PNGase) F resulted in the collapse of the different forms to faster migrating defined bands (Figure 6A). Accordingly, endogenous SLC38A9 was detected only after deglycosylation (Figure 6B).
  • SLC38A9 When co-expressed in HEK293T cells, SLC38A9 co-immunoprecipitated with LAMTOR1 (FIG IB). Furthermore, overexpressed LAMTOR1 bound endogenous SLC38A9 (FIG 1C). Importantly, we could validate complex membership entirely at the endogenous level in different human cell lines. With extract from HEK293T we used an antibody specific for SLC38A9 (commercially available from Sigma HPA043785) and detected coimmunoprecipitated RAGA and LAMTOR1 proteins (FIG ID). Conversely, immunoprecipitation of RAGA resulted in the specific recruitment of endogenous SLC38A9 (FIG ID).
  • SLC38A9 co-immunoprecipitated endogenous LAMTOR1, LAMTOR3, RAGA and RAGC, with both low and high bait expression levels (FIG 1H).
  • SLC38A9 co-immunoprecipitated endogenous LAMTOR1, LAMTOR3, RAGA and RAGC, with both low and high bait expression levels (FIG 1H).
  • SLC38A9 deletion constructs encoding the N-terminal cytoplasmic tail (amino acids 1-111, or amino acids 1-112) or the remaining eleven transmembrane-containing regions (113-561).
  • the cytoplasmic region of SLC38A9 retained the ability to interact with endogenous LAMTOR1, LAMTOR3, RAGA and RAGC proteins similar to the full-length protein, whereas binding was completely lost when the region was deleted (FIG 2D). This indicated that the cytoplasmic tail, devoid of any transmembrane region, is required and sufficient to bind the Ragulator/RAG GTPases complex.
  • N-terminal cytoplasmic region is evolutionary conserved across SLC38A9 proteins, we could not detect any significant homology with the N-terminal region of any of the other SLC38 family members. These results defined the unique cytoplasmic region of SLC38A9 as responsible for the interaction with the lysosomal mTOR-activating machinery and indicated that evolutionary conserved motifs are required for this interaction to occur.
  • SLC38A9 is competent for bidirectional transport of amino acids (FIG 3E). This suggests that SLC38A9 may be a low capacity transporter similar to SLC38A7 24 and resembling the properties of amino acid sensors described in yeast 26 and Drosophila 27 .
  • RAG GTPase The ability of RAG GTPase to recruit mTOR by binding Raptor is critically dependent on their nucleotide loading status that is in turn regulated by amino acid availability.
  • SLC38A9 interaction with RAG GTPase is dependent on their nucleotide loading we took advantage of widely used RAG nucleotide-binding mutants.
  • RAGA Q66L, RAGB Q99L and RAGC Q120L mutation abolished GTPase activity and therefore are loaded with GTP, whereas RAGA T21N, RAGB T54N and RAGC S75N have much lower affinity for all nucleotide with preferential binding to GDT.
  • SLC38A9 As a novel integral and druggable 32 component of the lysosomal machinery that controls mTORCl activity in response to amino acids (FIG 4E). SLC38A9 displays the characteristics expected for the missing lysosomal amino acid sensor required for activation of mTOR and we therefore name it herein Senior, for sensor of mTOR.
  • the present invention refers to the following nucleotide and amino acid sequences:
  • the present invention also provides techniques and methods wherein homologous sequences, and variants of the concise sequences provided herein are used. Preferably, such "variants" are genetic variants.
  • Nucleotide sequence encoding homo sapiens SLC38A9 (Senior) (NCBI genelD: 153129; Isoforml : NM_173514.3 -> NP_775785.2, complete sequence)
  • Nucleotide sequence encoding homo sapiens SLC38A9 (Senior) (NCBI genelD: 153129; Isoforml : NM_173514.3 -> NP_775785.2, open reading frame):
  • Amino acid sequence of homo sapiens SLC38A9 isoforml (NP_775785.2 ) : SEQ ID No. 4:
  • Nucleotide sequence encoding homo sapiens SLC38A9 (Senior) (NCBI genelD: 153129; Isoforml : NM_173514.3 -> NP_775785.2, open reading frame, mRNA):
  • nucleotide sequence of siRNA 1 (antisense sequence) targeting nucleotide sequence encoding homo sapiens SLC38A9 (Senior)
  • nucleotide sequence of siRNA 2 (antisense sequence) targeting nucleotide sequence encoding homo sapiens SLC38A9 (Sentor)
  • nucleotide sequence of siRNA 3 (antisense sequence) targeting nucleotide sequence encoding homo sapiens SLC38A9 (Sentor)
  • nucleotide sequence of siRNA 4 (antisense sequence) targeting nucleotide sequence encoding homo sapiens SLC38A9 (Sentor)
  • Nucleotide target sequence of human SLC38A9 mRNA (corresponding to nt 1931-1951 of human SLC38A9 mRNA (NMJ73514.3))
  • Nucleotide sequence encoding homo sapiens SLC38A9 (Sentor) (Isoform 2 : NM_001258286.1 -> NP_001245215.1, open reading frame):
  • Nucleotide sequence encoding homo sapiens SLC38A9 (Sentor) (Isoform 2 : NM_001258286.1 -> NP_001245215.1, mRNA):
  • Amino acid sequence of homo sapiens SLC38A9 isoform 2 (Isoform2 : NP 001245215.1) : SEQ ID No. 15:
  • Amino acid sequence of homo sapiens SLC38A9 isoform 3 (NP 001245216.1 ) : SEQ ID No. 18:
  • Nucleotide sequence encoding homo sapiens SLC38A9 (Sentor) (Isoform 4 : NM_001282429.1 -> NP_001269358.1, open reading frame):
  • Nucleotide sequence encoding homo sapiens SLC38A9 (Sentor) (Isoform 4 : NM_001282429.1 -> NP 001269358.1, mRNA):
  • Amino acid sequence of homo sapiens SLC38A9 isoform 4 (NP 001269358.1) : SEQ ID No. 21 :
  • Leucyl-tRNA synthetase is an intracellular leucine sensor for the mTORCl -signaling pathway.
  • An integrated workflow for charting the human interaction proteome insights into the PP2A system. Molecular systems biology 5, 237, doi: 10.1038/msb.2008.75 (2009).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP15727569.4A 2014-05-15 2015-05-15 Antagonisten von slc38a9 und deren verwendung in der therapie Withdrawn EP3143143A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14168539 2014-05-15
PCT/EP2015/060772 WO2015173398A1 (en) 2014-05-15 2015-05-15 Antagonists of slc38a9 and their use in therapy

Publications (1)

Publication Number Publication Date
EP3143143A1 true EP3143143A1 (de) 2017-03-22

Family

ID=50729382

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15727569.4A Withdrawn EP3143143A1 (de) 2014-05-15 2015-05-15 Antagonisten von slc38a9 und deren verwendung in der therapie

Country Status (3)

Country Link
US (1) US20170073690A1 (de)
EP (1) EP3143143A1 (de)
WO (1) WO2015173398A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015252840B2 (en) 2014-05-02 2017-05-18 Whitehead Institute For Biomedical Research Compositions and methods for modulating mTORC1
EP3191116B1 (de) 2014-09-12 2020-11-25 The Whitehead Institute for Biomedical Research Verfahren zur identifizierung von modulatoren der sestrin-gator2-interaktion und verwendung davon zur modulierung von mtorc1
US11092608B2 (en) 2015-12-28 2021-08-17 Whitehead Institute For Biomedical Research Methods of identifying modulators of CASTOR1-GATOR2 interaction and use of same to modulate mTORC1
WO2019232368A1 (en) * 2018-05-31 2019-12-05 Western University Of Health Sciences TARGETING P18 FOR mTOR-RELATED DISORDERS
EP3930729A4 (de) * 2019-02-27 2023-01-25 Tel Hashomer Medical Research Infrastructure and Services Ltd. Diagnose und behandlung von medulloblastom
US20220275376A1 (en) * 2019-08-20 2022-09-01 New York University Targeting slc38a2 in pancreatic cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
ATE12348T1 (de) 1980-11-10 1985-04-15 Gersonde Klaus Prof Dr Verfahren zur herstellung von lipid-vesikeln durch ultraschallbehandlung, anwendung des verfahrens und vorrichtung zur durchfuehrung des verfahrens.
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3486459D1 (de) 1983-09-26 1997-12-11 Udo Dr Med Ehrenfeld Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
GB9304200D0 (en) 1993-03-02 1993-04-21 Sandoz Ltd Improvements in or relating to organic compounds
EP0702722B1 (de) 1993-06-07 2005-08-03 Vical Incorporated Für die gentherapie verwendbare plasmide
JPH11509088A (ja) 1995-06-23 1999-08-17 プレジデント アンド フェローズ オブ ハーバード カレッジ 血管内皮増殖因子受容体をコードする遺伝子の転写調節

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2015173398A1 *

Also Published As

Publication number Publication date
US20170073690A1 (en) 2017-03-16
WO2015173398A1 (en) 2015-11-19

Similar Documents

Publication Publication Date Title
Tang et al. Selective inhibition of STRN3-containing PP2A phosphatase restores hippo tumor-suppressor activity in gastric cancer
Hou et al. A novel selective autophagy receptor, CCDC50, delivers K63 polyubiquitination-activated RIG-I/MDA5 for degradation during viral infection
Fischer et al. Sequestosome‐1 (p62) expression reveals chaperone‐assisted selective autophagy in immune‐mediated necrotizing myopathies
Kim et al. TFEB–GDF15 axis protects against obesity and insulin resistance as a lysosomal stress response
Feng et al. Store-independent activation of Orai1 by SPCA2 in mammary tumors
Green et al. APC and EB1 function together in mitosis to regulate spindle dynamics and chromosome alignment
US20170073690A1 (en) Antagonists of slc38a9 and their use in therapy
Girol et al. Anti-inflammatory mechanisms of the annexin A1 protein and its mimetic peptide Ac2-26 in models of ocular inflammation in vivo and in vitro
Parekh Store-operated CRAC channels: function in health and disease
Zhang et al. Amyloid-β induces hepatic insulin resistance in vivo via JAK2
Li et al. A novel ER-localized transmembrane protein, EMC6, interacts with RAB5A and regulates cell autophagy
Gastou et al. The severe phenotype of Diamond-Blackfan anemia is modulated by heat shock protein 70
Wang et al. Flightless I homolog negatively modulates the TLR pathway
Sakabe et al. TMEM33: a new stress-inducible endoplasmic reticulum transmembrane protein and modulator of the unfolded protein response signaling
MX2011001900A (es) Metodo para controlar metastasis de cancer o migracion de celulas de cancer modulando el nivel celular de lisil-tarn sintetasa.
Zhang et al. USP39 facilitates breast cancer cell proliferation through stabilization of FOXM1
Wei et al. Sigma‐1 receptor attenuates osteoclastogenesis by promoting ER‐associated degradation of SERCA2
Luo et al. ATF4 destabilizes RET through nonclassical GRP78 inhibition to enhance chemosensitivity to bortezomib in human osteosarcoma
Merlini et al. 201st ENMC International Workshop: Autophagy in muscular dystrophies–Translational approach, 1–3 November 2013, Bussum, The Netherlands
Gentilella et al. BAG3 expression in glioblastoma cells promotes accumulation of ubiquitinated clients in an Hsp70-dependent manner
Sanchez et al. The antiretroviral agent nelfinavir mesylate: a potential therapy for systemic sclerosis
Gao et al. NDP52 SUMOylation contributes to low‐dose X‐rays‐induced cardiac hypertrophy through PINK1/Parkin‐mediated mitophagy via MUL1/SUMO2 signalling
US20240238371A1 (en) Materials and methods for extracellular vesicle-associated diseases
Yan et al. GPNMB disrupts SNARE complex assembly to maintain bacterial proliferation within macrophages
Zhou et al. cGAS is a negative regulator of RIG-I–mediated IFN response in cyprinid fish

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20161215

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170714